这是一篇来自已证抗体库的有关人类 p21的综述,是根据504篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合p21 抗体。
p21 同义词: CAP20; CDKN1; CIP1; MDA-6; P21; SDI1; WAF1; p21CIP1

圣克鲁斯生物技术
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:200
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:200. Int J Mol Sci (2022) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:1000; 图 5d, 5e
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5d, 5e). iScience (2022) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:1000; 图 13
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 13). Int J Oncol (2022) ncbi
小鼠 单克隆(187)
  • 免疫组化-石蜡切片; 大鼠; 1:200; 图 7d
  • 免疫组化-石蜡切片; 小鼠; 1:200; 图 1j, 2g
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫组化-石蜡切片在大鼠样本上浓度为1:200 (图 7d) 和 被用于免疫组化-石蜡切片在小鼠样本上浓度为1:200 (图 1j, 2g). Int J Oral Sci (2022) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 6e, 6f
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 6e, 6f). Adv Sci (Weinh) (2022) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:3000; 图 4a, 7g
  • 免疫印迹; 人类; 1:3000; 图 4d, 8k
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:3000 (图 4a, 7g) 和 被用于免疫印迹在人类样本上浓度为1:3000 (图 4d, 8k). Clin Transl Med (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫组化; 人类; 图 s3i
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫组化在人类样本上 (图 s3i). Nat Commun (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 大鼠; 1:200; 图 5f
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, 6246)被用于被用于免疫印迹在大鼠样本上浓度为1:200 (图 5f). J Mol Med (Berl) (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:1000; 图 1b, 1e, 1h
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 1b, 1e, 1h). Proc Natl Acad Sci U S A (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:400; 图 6f
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:400 (图 6f). Int J Mol Sci (2021) ncbi
小鼠 单克隆(F-5)
  • mass cytometry; 小鼠; 图 s3
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于mass cytometry在小鼠样本上 (图 s3). EMBO J (2021) ncbi
小鼠 单克隆(DCS-60)
  • 免疫印迹; 人类; 1:200; 图 6a
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-56335)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 6a). Oxid Med Cell Longev (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 人类; 图 6a
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫组化-石蜡切片在人类样本上 (图 6a). Breast Cancer Res (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 5m
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc6246)被用于被用于免疫印迹在人类样本上 (图 5m). J Exp Clin Cancer Res (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:1000
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. Exp Neurol (2021) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:200; 图 2h
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:200 (图 2h). PLoS Genet (2020) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 大鼠; 图 5a
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-817)被用于被用于免疫印迹在大鼠样本上 (图 5a). Mol Med Rep (2020) ncbi
小鼠 单克隆(DCS-60)
  • 免疫印迹; 人类; 1:2500; 图 5d
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-56335)被用于被用于免疫印迹在人类样本上浓度为1:2500 (图 5d). Oncogene (2020) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 3g
圣克鲁斯生物技术 p21抗体(Santacruz Biotechnology, sc-817)被用于被用于免疫印迹在人类样本上 (图 3g). elife (2020) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:500; 图 3e
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 3e). EBioMedicine (2020) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 大鼠; 1:200; 图 5b
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在大鼠样本上浓度为1:200 (图 5b). Int J Nanomedicine (2020) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 小鼠; 1:500; 图 3d
  • 免疫印迹; 小鼠; 1:1000; 图 3a, 3b, 3c, s6c
圣克鲁斯生物技术 p21抗体(Santa Cruz, SC-6246)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:500 (图 3d) 和 被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3a, 3b, 3c, s6c). Nat Commun (2020) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 人类; 图 6d
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫组化-石蜡切片在人类样本上 (图 6d). Sci Rep (2020) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 s3e
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 s3e). Proc Natl Acad Sci U S A (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 2d
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在人类样本上 (图 2d). Nature (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:500; 图 s2e
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 s2e). Nature (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:250; 图 2h
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:250 (图 2h). elife (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 0.7 ug/ml; 图 4c
圣克鲁斯生物技术 p21抗体(Santa, F-5)被用于被用于免疫印迹在小鼠样本上浓度为0.7 ug/ml (图 4c). Science (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫细胞化学; 人类; 1:100; 图 e5c, e5e
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 e5c, e5e). Nature (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 s6c
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 s6c). Sci Adv (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:100; 图 s8a
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:100 (图 s8a). Cancer Cell (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 7c
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, F-5)被用于被用于免疫印迹在人类样本上 (图 7c). EMBO J (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 s7b
圣克鲁斯生物技术 p21抗体(Santa, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 s7b). Nature (2019) ncbi
小鼠 单克隆(B-2)
  • 免疫印迹; 小鼠; 1:50; 图 s1h, s2h
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-271532)被用于被用于免疫印迹在小鼠样本上浓度为1:50 (图 s1h, s2h). Hepatology (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 4d
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 4d). Cell Death Differ (2019) ncbi
小鼠 单克隆(F-5)
  • 免疫组化基因敲除验证; 人类; 1:200; 图 5a
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫组化基因敲除验证在人类样本上浓度为1:200 (图 5a). Genome Biol (2018) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 2e
圣克鲁斯生物技术 p21抗体(SantaCruz, sc-817)被用于被用于免疫印迹在人类样本上 (图 2e). Oncotarget (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:200; 图 4o
圣克鲁斯生物技术 p21抗体(SantaCruz, F-5)被用于被用于免疫印迹在小鼠样本上浓度为1:200 (图 4o). Genes Dev (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫沉淀; 小鼠; 图 5b
圣克鲁斯生物技术 p21抗体(Sana Cruz Biotechnology, Inc, sc-6246)被用于被用于免疫沉淀在小鼠样本上 (图 5b). Cancer Res (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 5c
圣克鲁斯生物技术 p21抗体(SantaCruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 5c). Oncogene (2017) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 3f
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫印迹在人类样本上 (图 3f). Life Sci (2017) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 小鼠; 1:1000; 图 2g
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 2g). Sci Rep (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 3d
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 3d). J Clin Invest (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:500; 图 7a
圣克鲁斯生物技术 p21抗体(Santa Cruz, SC-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 7a). Cell Rep (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 4b
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 4b). PLoS ONE (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 小鼠; 1:100; 图 5d
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:100 (图 5d). Sci Rep (2017) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 5d
圣克鲁斯生物技术 p21抗体(Santa Cruz, SC-817)被用于被用于免疫印迹在人类样本上 (图 5d). Cancer Med (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹基因敲除验证; 小鼠; 图 3d
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹基因敲除验证在小鼠样本上 (图 3d). Mol Pharmacol (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:1000; 图 5a
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). Mol Med Rep (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 大鼠; 1:250; 图 3a
圣克鲁斯生物技术 p21抗体(Santa Cruz, Sc-6246)被用于被用于免疫印迹在大鼠样本上浓度为1:250 (图 3a). Alcohol (2016) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 7d
圣克鲁斯生物技术 p21抗体(SantaCruz, 187)被用于被用于免疫印迹在人类样本上 (图 7d). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:200; 图 6c
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 6c). Mol Cell Endocrinol (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹基因敲除验证; 小鼠; 图 3h
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹基因敲除验证在小鼠样本上 (图 3h). Peptides (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 1f
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-53870)被用于被用于免疫印迹在人类样本上 (图 1f). Oncogene (2017) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:500; 图 4a
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 4a). Oncotarget (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 3b
圣克鲁斯生物技术 p21抗体(Santa-Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 3b). Oncotarget (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫细胞化学; 人类; 图 1f
  • 免疫印迹; 人类; 图 1b
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, SC-6246)被用于被用于免疫细胞化学在人类样本上 (图 1f) 和 被用于免疫印迹在人类样本上 (图 1b). Sci Rep (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 1c
圣克鲁斯生物技术 p21抗体(Santa Cruz, F-5)被用于被用于免疫印迹在人类样本上 (图 1c). Oncotarget (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 s4
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, F-5)被用于被用于免疫印迹在人类样本上 (图 s4). Nucleic Acids Res (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 s1
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 s1). Cell Death Dis (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-冰冻切片; 小鼠; 图 3
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 3). Oncotarget (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 5
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 5). Sci Rep (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:1000; 图 3a
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3a). Oncotarget (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:500; 图 8
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 8). PLoS ONE (2016) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 3a
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, 817)被用于被用于免疫印迹在人类样本上 (图 3a). EMBO Rep (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 5c
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 5c). Oncogene (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 s2
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 s2). Sci Rep (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:500; 图 st3
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 st3). Nat Commun (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:200; 图 3
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 3). Cell Death Dis (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 5
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 5). Oncotarget (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 6
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc53870)被用于被用于免疫印迹在人类样本上 (图 6). Oncotarget (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:500; 图 7a
圣克鲁斯生物技术 p21抗体(SantaCruz, F-5)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 7a). Nat Commun (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:50; 图 1d
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:50 (图 1d). Aging Cell (2016) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 9
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫印迹在人类样本上 (图 9). Genes Cancer (2015) ncbi
小鼠 单克隆(B-2)
  • 免疫印迹; 小鼠; 1:400; 图 5
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-271532)被用于被用于免疫印迹在小鼠样本上浓度为1:400 (图 5). Exp Ther Med (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 大鼠; 图 5
圣克鲁斯生物技术 p21抗体(Santacruz, sc-6246)被用于被用于免疫印迹在大鼠样本上 (图 5). Physiol Rep (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:500; 图 3
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 3). J Clin Invest (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 8
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 8). PLoS ONE (2015) ncbi
小鼠 单克隆(SPM306)
  • 免疫印迹; 人类; 图 2
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-65595)被用于被用于免疫印迹在人类样本上 (图 2). Mol Cancer (2015) ncbi
小鼠 单克隆(187)
  • 免疫组化; 人类; 图 1
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫组化在人类样本上 (图 1). Mol Cancer (2015) ncbi
小鼠 单克隆(SPM306)
  • 免疫印迹; 人类; 图 3
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-65595)被用于被用于免疫印迹在人类样本上 (图 3). Oncotarget (2015) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 4
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫印迹在人类样本上 (图 4). Oncogene (2016) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 6
圣克鲁斯生物技术 p21抗体(santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 6). Oncotarget (2015) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 1:500; 图 7
圣克鲁斯生物技术 p21抗体(Santa cruz, sc-817)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 7). PLoS ONE (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 2
圣克鲁斯生物技术 p21抗体(santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 2). Sci Rep (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上. J Proteomics (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上. Int J Oncol (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:500; 图 1
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:500 (图 1). Oncotarget (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 4a
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在人类样本上 (图 4a). Oncotarget (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹基因敲除验证; 小鼠; 1:1000
圣克鲁斯生物技术 p21抗体(Santa, sc-6246)被用于被用于免疫印迹基因敲除验证在小鼠样本上浓度为1:1000. PLoS ONE (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 1
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 1). Oncotarget (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫沉淀在人类样本上 和 被用于免疫印迹在人类样本上. J Biol Chem (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫细胞化学; 人类; 图 1
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫细胞化学在人类样本上 (图 1). EMBO J (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 6
圣克鲁斯生物技术 p21抗体(santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 6). PLoS Genet (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上. J Clin Invest (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上. J Clin Invest (2015) ncbi
小鼠 单克隆(DCS-60)
  • 免疫印迹; 人类; 图 2
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-56335)被用于被用于免疫印迹在人类样本上 (图 2). Cell Cycle (2015) ncbi
小鼠 单克隆(F-5)
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于. Aging Cell (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 s2
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 s2). Sci Rep (2015) ncbi
小鼠 单克隆(DCS-60)
  • 免疫印迹; 人类; 1:200; 图 4
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-56335)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 4). Oncol Lett (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 4
圣克鲁斯生物技术 p21抗体(Santa Cruz, F-5)被用于被用于免疫印迹在人类样本上 (图 4). Mol Cancer (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:300; 图 5
圣克鲁斯生物技术 p21抗体(Santa Cruz, F-5)被用于被用于免疫印迹在小鼠样本上浓度为1:300 (图 5). Development (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 4f
圣克鲁斯生物技术 p21抗体(Santa, sc-53870)被用于被用于免疫印迹在人类样本上 (图 4f). Hum Mol Genet (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:500
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:500. Free Radic Biol Med (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:1000
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:1000. Biochim Biophys Acta (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 3c
圣克鲁斯生物技术 p21抗体(Santa Cruz, F-5)被用于被用于免疫印迹在人类样本上 (图 3c). Mol Pharm (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:1000
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, SC-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. Am J Physiol Endocrinol Metab (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上. Nat Commun (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 人类; 1:50
  • 免疫印迹; 人类; 1:500
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 和 被用于免疫印迹在人类样本上浓度为1:500. Oncotarget (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫细胞化学; 小鼠
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫细胞化学在小鼠样本上 和 被用于免疫印迹在小鼠样本上. Biochim Biophys Acta (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 小鼠
圣克鲁斯生物技术 p21抗体(Santa cruz, SC-6246)被用于被用于免疫组化-石蜡切片在小鼠样本上. Oncotarget (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 1:200
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-53870)被用于被用于免疫印迹在小鼠样本上浓度为1:200. Cell Physiol Biochem (2014) ncbi
小鼠 单克隆(SPM306)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-65595)被用于被用于免疫印迹在人类样本上. PLoS ONE (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 1
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上 (图 1). Biochim Biophys Acta (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 0.2 ug/ml
圣克鲁斯生物技术 p21抗体(Santa, sc-6246)被用于被用于免疫印迹在人类样本上浓度为0.2 ug/ml. PLoS ONE (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, F-5)被用于被用于免疫印迹在小鼠样本上 和 被用于免疫印迹在人类样本上. Oncogene (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 6d
圣克鲁斯生物技术 p21抗体(Santa, sc6246)被用于被用于免疫印迹在人类样本上 (图 6d). Oncotarget (2014) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 2
圣克鲁斯生物技术 p21抗体(santa Cruz, sc-817)被用于被用于免疫印迹在人类样本上 (图 2). Oncogene (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上. Cancer Res (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 6
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在人类样本上 (图 6). J Pathol (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:1000
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotech, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. J Neural Transm (Vienna) (2015) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 1
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 1). J Am Soc Nephrol (2014) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817X)被用于被用于免疫印迹在人类样本上. Cell Death Dis (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上. Exp Cell Res (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-53870)被用于被用于免疫印迹在人类样本上. Cell Death Dis (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 1:100; 图 3c
圣克鲁斯生物技术 p21抗体(Santa, sc-6246)被用于被用于免疫印迹在人类样本上浓度为1:100 (图 3c). Genes Dev (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc6246)被用于被用于免疫组化-石蜡切片在小鼠样本上. Exp Toxicol Pathol (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 5
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 5). Mol Pharmacol (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类; 图 6
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, F-5)被用于被用于免疫印迹在人类样本上 (图 6). Blood (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫组化-石蜡切片; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc6246)被用于被用于免疫组化-石蜡切片在小鼠样本上. Exp Toxicol Pathol (2013) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在人类样本上. Cancer Cell Int (2013) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc6246)被用于被用于免疫印迹在小鼠样本上. Oncogene (2014) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 1:1000
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. Mol Cancer Res (2012) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 4
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 4). Proc Natl Acad Sci U S A (2012) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠; 图 1
圣克鲁斯生物技术 p21抗体(Santa, sc-6246)被用于被用于免疫印迹在小鼠样本上 (图 1). Cell Cycle (2011) ncbi
小鼠 单克隆(187)
  • 免疫印迹; 人类; 图 3
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-817)被用于被用于免疫印迹在人类样本上 (图 3). Clin Cancer Res (2010) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-6246)被用于被用于免疫印迹在小鼠样本上. Mol Cell Biol (2010) ncbi
小鼠 单克隆(187)
  • 免疫沉淀; 人类; 1 ug/time
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz Biotechnology, sc-817)被用于被用于免疫沉淀在人类样本上浓度为1 ug/time 和 被用于免疫印迹在人类样本上. Oncogene (2007) ncbi
小鼠 单克隆(F-5)
  • 免疫印迹; 人类
圣克鲁斯生物技术 p21抗体(Santa Cruz, sc-6246)被用于被用于免疫印迹在人类样本上. FEBS Lett (2006) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 单克隆(EPR3993)
  • 免疫组化-石蜡切片; 小鼠; 图 s8b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, Ab109199)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 s8b). Oncogene (2022) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 1:500; 图 4b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 4b). JCI Insight (2021) ncbi
domestic rabbit 单克隆
  • 免疫印迹; 人类; 1:500; 图 4c
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab218311)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 4c). Int J Oncol (2021) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫组化; 大鼠; 1:100; 图 1b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫组化在大鼠样本上浓度为1:100 (图 1b). Oxid Med Cell Longev (2021) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 图 s4s
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上 (图 s4s). Cell Metab (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 大鼠; 图 s4b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在大鼠样本上 (图 s4b). J Cell Biol (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫印迹; 小鼠; 1:1000; 图 6b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, 188224)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 6b). Front Cell Dev Biol (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫组化; 小鼠; 1:2000; 图 7c
艾博抗(上海)贸易有限公司 p21抗体(Abcam, Ab188224)被用于被用于免疫组化在小鼠样本上浓度为1:2000 (图 7c). Front Pharmacol (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫组化; 小鼠; 1:1000; 图 3d
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫组化在小鼠样本上浓度为1:1000 (图 3d). Metabolites (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫组化; pigs ; 图 4g
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫组化在pigs 样本上 (图 4g). Sci Rep (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫印迹; 人类; 图 3j
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫印迹在人类样本上 (图 3j). Cell Death Dis (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 图 4b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上 (图 4b). Aging Cell (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 图 1j
艾博抗(上海)贸易有限公司 p21抗体(Abcam, EPR3993)被用于被用于免疫印迹在小鼠样本上 (图 1j). J Clin Invest (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫组化-石蜡切片; 小鼠; 1:50; 图 1c
  • 免疫印迹; 小鼠; 1:1000; 图 1e
  • 免疫印迹; 大鼠; 1:1000; 图 2g
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:50 (图 1c), 被用于免疫印迹在小鼠样本上浓度为1:1000 (图 1e) 和 被用于免疫印迹在大鼠样本上浓度为1:1000 (图 2g). Aging (Albany NY) (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 1:1000; 图 3f
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3f). PLoS ONE (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 人类; 1:1000; 图 3a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3a). World J Surg Oncol (2021) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 1:1000; 图 7a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7a). Nat Commun (2021) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 小鼠; 图 3i
  • 免疫印迹; 人类; 1:1000; 图 3h
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在小鼠样本上 (图 3i) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 3h). Cell Death Dis (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫印迹; 人类; 1:1000; 图 5a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). Cancer Cell Int (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 人类; 1:1000
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在人类样本上浓度为1:1000. Aging (Albany NY) (2021) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫印迹基因敲除验证; 小鼠; 1:500; 图 1f
  • 免疫沉淀; 小鼠; 图 6a
  • 免疫组化; 小鼠; 1:500; 图 3b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫印迹基因敲除验证在小鼠样本上浓度为1:500 (图 1f), 被用于免疫沉淀在小鼠样本上 (图 6a) 和 被用于免疫组化在小鼠样本上浓度为1:500 (图 3b). Cell Mol Gastroenterol Hepatol (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 大鼠; 图 9e
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在大鼠样本上 (图 9e). Theranostics (2021) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 1:250; 图 6a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上浓度为1:250 (图 6a). Cancer Res Treat (2021) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 1:1000; 图 2c
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 2c). Adipocyte (2020) ncbi
domestic rabbit 单克隆(EPR3993)
  • 流式细胞仪; 人类; 1:200; 图 s5c
  • 免疫印迹; 人类; 1:1000; 图 s2b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于流式细胞仪在人类样本上浓度为1:200 (图 s5c) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 s2b). Science (2020) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 图 6d
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上 (图 6d). Am J Cancer Res (2020) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫印迹; 人类; 1:2000; 图 5e
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 5e). Aging (Albany NY) (2020) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫印迹; 小鼠; 1:1000; 图 3f, 7b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3f, 7b). Aging (Albany NY) (2020) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫沉淀; 小鼠; 图 2a
  • 免疫印迹; 小鼠; 图 1a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab188224)被用于被用于免疫沉淀在小鼠样本上 (图 2a) 和 被用于免疫印迹在小鼠样本上 (图 1a). Aging (Albany NY) (2019) ncbi
domestic rabbit 单克隆
  • 免疫印迹; 人类; 图 4h
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab218311)被用于被用于免疫印迹在人类样本上 (图 4h). Aging (Albany NY) (2019) ncbi
domestic rabbit 单克隆(EPR18021)
  • 免疫组化-冰冻切片; 小鼠; 图 7d
艾博抗(上海)贸易有限公司 p21抗体(AbCam, ab188224)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 7d). Cell Stem Cell (2019) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 1:1000; 图 3c
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3c). Biosci Rep (2019) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 大鼠; 1:1000; 图 5b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在大鼠样本上浓度为1:1000 (图 5b). Cell Death Dis (2019) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 大鼠; 图 2b
  • 免疫印迹; 人类; 1:1500; 图 2b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在大鼠样本上 (图 2b) 和 被用于免疫印迹在人类样本上浓度为1:1500 (图 2b). J Exp Clin Cancer Res (2019) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 大鼠; 图 1b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在大鼠样本上 (图 1b). Braz J Med Biol Res (2019) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫组化-冰冻切片; 小鼠; 1:200; 图 2a
  • 免疫细胞化学; 小鼠; 1:200; 图 3c
  • 免疫印迹; 小鼠; 图 3a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫组化-冰冻切片在小鼠样本上浓度为1:200 (图 2a), 被用于免疫细胞化学在小鼠样本上浓度为1:200 (图 3c) 和 被用于免疫印迹在小鼠样本上 (图 3a). Biomed Pharmacother (2019) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 图 2d
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上 (图 2d). Biochem Biophys Res Commun (2018) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 大鼠; 1:1000; 图 6c
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在大鼠样本上浓度为1:1000 (图 6c). Biosci Rep (2018) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 图 6c
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上 (图 6c). Cell Signal (2018) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫组化; 小鼠; 1:500; 图 8f
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫组化在小鼠样本上浓度为1:500 (图 8f). Cell Death Dis (2018) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 人类; 图 3g
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在人类样本上 (图 3g). Science (2017) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 1:1000; 图 4f
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 4f). Redox Biol (2017) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 1:1000; 图 5a
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). Int J Mol Sci (2016) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 1:1000; 图 s1
艾博抗(上海)贸易有限公司 p21抗体(abcam, ab109199)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 s1). Sci Rep (2016) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹基因敲除验证; 人类; 1:2000; 图 4
  • 免疫细胞化学; 人类; 1:200; 图 4
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:2000 (图 4) 和 被用于免疫细胞化学在人类样本上浓度为1:200 (图 4). Nat Commun (2016) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 1:500; 图 5
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 5). Biol Open (2016) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 图 5d
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上 (图 5d). Stem Cells Int (2016) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠; 1:1000; 图 3b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3b). FEBS Open Bio (2015) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 图 2
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上 (图 2). Int J Mol Sci (2015) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 人类; 1:2000; 图 1b
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 1b). Oncotarget (2015) ncbi
domestic rabbit 单克隆(EPR3993)
  • 免疫印迹; 小鼠
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109199)被用于被用于免疫印迹在小鼠样本上. PLoS ONE (2015) ncbi
domestic rabbit 单克隆(EPR362)
  • 免疫印迹; 人类; 1:1000; 图 5
艾博抗(上海)贸易有限公司 p21抗体(Abcam, ab109520)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5). Cell Mol Life Sci (2015) ncbi
赛默飞世尔
domestic rabbit 多克隆
  • 免疫组化; 人类; 图 3j
赛默飞世尔 p21抗体(ThermoFisher, PA5-14456)被用于被用于免疫组化在人类样本上 (图 3j). Circulation (2021) ncbi
domestic rabbit 单克隆(R.229.6)
  • 免疫细胞化学; 人类; 1:800; 图 2d
赛默飞世尔 p21抗体(Thermo Fisher, MA5-14949)被用于被用于免疫细胞化学在人类样本上浓度为1:800 (图 2d). Aging (Albany NY) (2021) ncbi
小鼠 单克隆(HJ21)
  • 免疫组化; 小鼠; 图 5b
赛默飞世尔 p21抗体(Invitrogen, AHZ0422)被用于被用于免疫组化在小鼠样本上 (图 5b). Exp Mol Med (2021) ncbi
domestic rabbit 重组(2H2L13)
  • 免疫细胞化学; 人类; 图 5a
  • 免疫印迹; 人类; 图 5a
赛默飞世尔 p21抗体(Thermo Fischer Scientific, PA5-701151)被用于被用于免疫细胞化学在人类样本上 (图 5a) 和 被用于免疫印迹在人类样本上 (图 5a). Toxicol In Vitro (2017) ncbi
domestic rabbit 重组(2H2L13)
  • 免疫细胞化学; 人类; 图 3f
  • 免疫印迹; 人类; 图 3e
赛默飞世尔 p21抗体(Thermo Scientific, PA5-701151)被用于被用于免疫细胞化学在人类样本上 (图 3f) 和 被用于免疫印迹在人类样本上 (图 3e). Exp Cell Res (2017) ncbi
domestic rabbit 单克隆(R.229.6)
  • 免疫细胞化学; 人类; 1:300; 图 3
赛默飞世尔 p21抗体(Pierce, R.229.6)被用于被用于免疫细胞化学在人类样本上浓度为1:300 (图 3). Springerplus (2016) ncbi
domestic rabbit 单克隆(R.229.6)
  • 免疫组化; 人类; 1:50
赛默飞世尔 p21抗体(Pierce, MA5-14949)被用于被用于免疫组化在人类样本上浓度为1:50. Histochem Cell Biol (2016) ncbi
小鼠 单克隆(HJ21)
  • 免疫印迹; 小鼠; 图 5
赛默飞世尔 p21抗体(Invitrogen, AHZ0422)被用于被用于免疫印迹在小鼠样本上 (图 5). Cell Cycle (2016) ncbi
domestic rabbit 多克隆
赛默飞世尔 p21抗体(Pierce, PA5-12646)被用于. Oncotarget (2015) ncbi
domestic rabbit 单克隆(R.229.6)
  • 免疫印迹; 人类; 图 3a
赛默飞世尔 p21抗体(Pierce, MA5-14949)被用于被用于免疫印迹在人类样本上 (图 3a). Cell Cycle (2015) ncbi
小鼠 单克隆(HJ21)
  • 免疫细胞化学; 人类; 1:100; 图 6
  • 免疫印迹; 人类; 1:5000; 图 4
赛默飞世尔 p21抗体(Invitrogen, AHZ0422)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 6) 和 被用于免疫印迹在人类样本上浓度为1:5000 (图 4). Cell Cycle (2013) ncbi
小鼠 单克隆(HJ21)
  • 免疫印迹; 小鼠; 1:50; 图 1
赛默飞世尔 p21抗体(Invitrogen, AHZ0422)被用于被用于免疫印迹在小鼠样本上浓度为1:50 (图 1). Biochimie (2011) ncbi
Novus Biologicals
domestic rabbit 多克隆
  • 免疫组化; 小鼠; 1:200; 图 1h
Novus Biologicals p21抗体(Novus, NB100-1941)被用于被用于免疫组化在小鼠样本上浓度为1:200 (图 1h). Nat Commun (2021) ncbi
domestic rabbit 多克隆
  • 免疫组化; 小鼠; 图 2c
  • 免疫印迹; 小鼠; 图 2h
Novus Biologicals p21抗体(NOVUS, NB100-1941)被用于被用于免疫组化在小鼠样本上 (图 2c) 和 被用于免疫印迹在小鼠样本上 (图 2h). Signal Transduct Target Ther (2021) ncbi
小鼠 单克隆(WA-1)
  • 免疫印迹; 小鼠; 图 4a
Novus Biologicals p21抗体(Novus, NBP2-29463)被用于被用于免疫印迹在小鼠样本上 (图 4a). Proc Natl Acad Sci U S A (2021) ncbi
小鼠 单克隆(WA-1)
  • 免疫印迹; 小鼠; 1:50; 图 7a
Novus Biologicals p21抗体(Novus, NBP2-29463)被用于被用于免疫印迹在小鼠样本上浓度为1:50 (图 7a). Proc Natl Acad Sci U S A (2017) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2c). Mol Ther Oncolytics (2022) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 小鼠; 1:50; 图 3e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫组化在小鼠样本上浓度为1:50 (图 3e). Theranostics (2022) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 人类; 图 6c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947S)被用于被用于免疫组化在人类样本上 (图 6c). Cell Death Dis (2022) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4k, 6e, s4d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4k, 6e, s4d). Clin Transl Med (2022) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 图 6i, 6j
  • 免疫印迹; 人类; 图 5f
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫组化-石蜡切片在人类样本上 (图 6i, 6j) 和 被用于免疫印迹在人类样本上 (图 5f). Cell Death Dis (2022) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 小鼠; 图 4d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在小鼠样本上 (图 4d). Int J Mol Sci (2022) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 4e). Cell Rep (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3c
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947 s)被用于被用于免疫印迹在人类样本上 (图 3c). Sci Rep (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 4d, 4e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4d, 4e). Neurooncol Adv (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s1f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947T)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s1f). Nat Commun (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). Sci Adv (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 5f). Sci Adv (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3b). Clin Transl Med (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠; 1:1000; 图 6b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 6b). Neural Regen Res (2022) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫沉淀; 人类; 图 5d
  • 免疫印迹; 人类; 图 4f
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫沉淀在人类样本上 (图 5d) 和 被用于免疫印迹在人类样本上 (图 4f). Cell Death Dis (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 3c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 3c). J Hematol Oncol (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4a). Nat Commun (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2f
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在人类样本上 (图 2f). Cell Rep (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 人类; 图 5f
  • 免疫印迹; 人类; 1:100; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫组化在人类样本上 (图 5f) 和 被用于免疫印迹在人类样本上浓度为1:100 (图 4a). Cell Death Dis (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 2e). Cell Death Dis (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 1h
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling, 2947S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1h). EMBO J (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:500; 图 3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947s)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 3b). Cell Death Differ (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 s3b). Oncogenesis (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 3c). Breast Cancer Res (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 7i, s7b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7i, s7b). Cell Stem Cell (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4d
赛信通(上海)生物试剂有限公司 p21抗体(cell signaling technology, 2947)被用于被用于免疫印迹在人类样本上 (图 4d). Front Oncol (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 图 1b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling, 2947S)被用于被用于免疫细胞化学在人类样本上 (图 1b). Genes Dev (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5f). Basic Res Cardiol (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 1:1000; 图 4j
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling, 12D1)被用于被用于免疫细胞化学在人类样本上浓度为1:1000 (图 4j). Aging Cell (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5a
赛信通(上海)生物试剂有限公司 p21抗体(CST, 12D1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). Sci Rep (2021) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 小鼠; 1:1000; 图 7g
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 7g). J Immunother Cancer (2021) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 3c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2946)被用于被用于免疫印迹在人类样本上 (图 3c). Onco Targets Ther (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 5c). Cell Death Discov (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s8b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 s8b). J Clin Invest (2021) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 4b). Mol Oncol (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3d
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在人类样本上 (图 3d). Mol Cell Biol (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠; 图 2c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在小鼠样本上 (图 2c). elife (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1m
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1m). Nucleic Acids Res (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 5c). Oncogenesis (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 7d
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 7d). Mol Cancer (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 其他; 人类; 1:200
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling Technology, 2947S)被用于被用于其他在人类样本上浓度为1:200. elife (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠; 图 3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在小鼠样本上 (图 3b). Aging (Albany NY) (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1h
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 1h). Nature (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4g
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4g). Mol Oncol (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 7c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7c). Science (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). Nat Commun (2019) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 5a
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2946)被用于被用于免疫印迹在人类样本上 (图 5a). Oncogene (2020) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 人类; 1:250; 图 7g
  • 免疫印迹; 人类; 1:3000; 图 6b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫组化在人类样本上浓度为1:250 (图 7g) 和 被用于免疫印迹在人类样本上浓度为1:3000 (图 6b). Cell Stem Cell (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4c, s3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4c, s3b). Cell Death Dis (2019) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 1:2000; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2946S)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 5). Biomolecules (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4a). Biosci Rep (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3a, s2g
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 3a, s2g). Science (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 人类; 图 2g
  • 免疫印迹; 人类; 图 2e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫组化在人类样本上 (图 2g) 和 被用于免疫印迹在人类样本上 (图 2e). Cancer Cell (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5b
赛信通(上海)生物试剂有限公司 p21抗体(cell signaling technologies, 2947)被用于被用于免疫印迹在人类样本上 (图 5b). Front Genet (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:750; 图 5e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947 S)被用于被用于免疫印迹在人类样本上浓度为1:750 (图 5e). Nat Commun (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 图 1c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947S)被用于被用于免疫细胞化学在人类样本上 (图 1c). Cell (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 1:100; 图 5g
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 5g). elife (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s2c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2c). Nat Commun (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947s)被用于被用于免疫印迹在人类样本上 (图 2d). PLoS Biol (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1e
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在人类样本上 (图 1e). Cell Rep (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 流式细胞仪; 人类; 图 8d
  • 免疫印迹; 人类; 图 6e, 7b
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947S)被用于被用于流式细胞仪在人类样本上 (图 8d) 和 被用于免疫印迹在人类样本上 (图 6e, 7b). Cell Death Dis (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling Technologies, 2947S)被用于被用于免疫印迹在人类样本上 (图 3d). Cell Death Dis (2019) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 e1b, e1d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling, DCS60)被用于被用于免疫印迹在人类样本上 (图 e1b, e1d). Nature (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1f). J Exp Med (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s2a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 s2a). Genes Dev (2019) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 s3f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2946)被用于被用于免疫印迹在人类样本上 (图 s3f). Cell (2019) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s8c, s8d
  • 免疫组化-石蜡切片; 小鼠; 图 s8a
  • 免疫印迹; 小鼠; 图 s8b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 s8c, s8d), 被用于免疫组化-石蜡切片在小鼠样本上 (图 s8a) 和 被用于免疫印迹在小鼠样本上 (图 s8b). Hepatology (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5d). Oncol Rep (2019) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 2b). Nat Chem Biol (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s1h
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947s)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s1h). Nat Commun (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s5e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s5e). J Clin Invest (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在人类样本上 (图 1c). Oncotarget (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 图 s6i
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫组化-石蜡切片在人类样本上 (图 s6i). Nat Commun (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2b). Cancer Chemother Pharmacol (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 7a
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在人类样本上 (图 7a). PLoS Pathog (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1l
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在人类样本上 (图 1l). PLoS ONE (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹基因敲除验证; 人类; 1:1000; 图 7b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:1000 (图 7b). Cell Death Dis (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 小鼠; 图 2a
  • 免疫印迹; 人类; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫组化在小鼠样本上 (图 2a) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 4a). Oncogene (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5i
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947S)被用于被用于免疫印迹在人类样本上 (图 5i). Cell (2018) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 1c). Sci Rep (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:500; 图 2f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947T)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 2f). Oncotarget (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2c). Clin Cancer Res (2018) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠; 1:1000; 图 3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3b). Cancer Discov (2017) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 2g
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 2g). Oncogene (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4d). Int J Radiat Biol (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 6e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947s)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6e). Sci Rep (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 7a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 7a). Mol Med Rep (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3c
赛信通(上海)生物试剂有限公司 p21抗体(cell signalling, 2947p)被用于被用于免疫印迹在人类样本上 (图 3c). PLoS Pathog (2017) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 5e
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 5e). Redox Biol (2017) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 小鼠; 图 1a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在小鼠样本上 (图 1a). EMBO J (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(cell signalling, 2947P)被用于被用于免疫印迹在人类样本上浓度为1:1000. Oncoscience (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 2f
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 2f). Oncotarget (2017) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2946)被用于被用于免疫印迹在人类样本上 (图 4a). Int J Mol Sci (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 7c
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 7c). Oncotarget (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 1a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1a). Arch Biochem Biophys (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2a). Sci Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4c). Sci Rep (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 4d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, DCS60)被用于被用于免疫印迹在人类样本上 (图 4d). Clin Cancer Res (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 7g
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 7g). Sci Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4c). Sci Rep (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 1:2000; 图 7d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 7d). EMBO Mol Med (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 6b
  • 免疫印迹; 人类; 图 6c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 6b) 和 被用于免疫印迹在人类样本上 (图 6c). Cancer Lett (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 图 4
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫细胞化学在人类样本上 (图 4). Sci Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 图 4
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫细胞化学在人类样本上 (图 4) 和 被用于免疫印迹在人类样本上 (图 2). BMC Cancer (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2b). Eur J Cancer (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Tech, 2947)被用于被用于免疫印迹在人类样本上 (图 4). Sci Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:200; 图 st1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:200 (图 st1). Nat Commun (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 5f). Cancer Res (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 6b
赛信通(上海)生物试剂有限公司 p21抗体(cell signalling, 2946)被用于被用于免疫印迹在人类样本上 (图 6b). Breast Cancer Res (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 6i
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 6i). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Sci Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s3b). Oncogene (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在人类样本上 (图 4a). Oncogene (2017) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 6a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 6a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:2000; 图 2B
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 2B). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5e
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947S)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5e). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Tech, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). J Cell Biol (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 5b). J Proteomics (2017) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 7e
赛信通(上海)生物试剂有限公司 p21抗体(cell signalling, 2946)被用于被用于免疫印迹在人类样本上 (图 7e). EMBO Mol Med (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:2000; 图 s5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 s5). Nat Commun (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 s2a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 s2a). J Mol Med (Berl) (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 3e
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3e). Aging (Albany NY) (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 5). Sci Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s9
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Tech, 2947S)被用于被用于免疫印迹在人类样本上 (图 s9). Nat Commun (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947P)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1a). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s1
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s1). EMBO Mol Med (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1d). Oncol Rep (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 1:1000; 图 6
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Tech, 2946)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 6). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 8
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 8). Oncogenesis (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 s2). Autophagy (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 0.5 ug/ml; 图 st1
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947S)被用于被用于免疫组化-石蜡切片在人类样本上浓度为0.5 ug/ml (图 st1). Nature (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠; 1:1000; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 5). Nat Commun (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalng, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Tech, 2947)被用于被用于免疫印迹在人类样本上 (图 3). Cancer Sci (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 3). Sci Rep (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 s1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 s1). BMC Cancer (2016) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 1e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 1e). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于. elife (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s11e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s11e). Nat Commun (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(New England Biolabs, 2947)被用于被用于免疫印迹在人类样本上 (图 4a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 5). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1c). J Biol Chem (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 3). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 6f
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 6f). Stem Cells Dev (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling, 2947)被用于被用于免疫印迹在人类样本上 (图 1). Cell Death Dis (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5d). Mol Med Rep (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 12D1)被用于被用于免疫印迹在人类样本上 (图 2b). Immunol Res (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上 (图 5). Mol Cell Proteomics (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 5a). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 S1B
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947)被用于被用于免疫印迹在人类样本上 (图 S1B). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Nat Cell Biol (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signalling, 2947)被用于被用于免疫印迹在人类样本上 (图 2). Oncotarget (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2). Oncogene (2016) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 6a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947P)被用于被用于免疫印迹在人类样本上 (图 6a). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 1:100; 图 s3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 s3). Oncotarget (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, DCS60)被用于被用于免疫印迹在人类样本上 (图 3). Mol Cancer Ther (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹基因敲除验证; 人类; 1:1000; 图 6
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947S)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:1000 (图 6). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 4c, d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4c, d). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 12D1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Oncotarget (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫沉淀; 人类; 1:50; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, DCS60)被用于被用于免疫沉淀在人类样本上浓度为1:50 (图 2). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technologies, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 2). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 3d
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 3d). PLoS ONE (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 6). J Virol (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 图 6a
  • 免疫印迹; 人类; 1:1000; 图 3b
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947S)被用于被用于免疫细胞化学在人类样本上 (图 6a) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 3b). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 4). Drug Des Devel Ther (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3). Nat Chem (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 5b
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5b). Mol Med Rep (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 4a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 12D1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4a). PLoS ONE (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上 (图 6). PLoS ONE (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s8
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s8). Nat Commun (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1). J Biomed Sci (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:500; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 1). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947P)被用于被用于免疫印迹在人类样本上. Nucleic Acids Res (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 图 1
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Tech, 2947)被用于被用于免疫细胞化学在人类样本上 (图 1) 和 被用于免疫印迹在人类样本上 (图 1). BMC Cancer (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s5). Sci Rep (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 12D1)被用于被用于免疫印迹在人类样本上浓度为1:1000. BMC Cancer (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, CS2947)被用于被用于免疫印迹在人类样本上 (图 5). PLoS ONE (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2946)被用于被用于免疫印迹在人类样本上 (图 3). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 s8
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 12D1)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s8). Nat Cell Biol (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上. Oxid Med Cell Longev (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. J Biol Chem (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 1a
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 1a). Int J Oral Sci (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 12D1)被用于被用于免疫印迹在人类样本上. Nucleic Acids Res (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 1185)被用于被用于免疫印迹在人类样本上浓度为1:1000. PLoS ONE (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. Int J Oncol (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 1). Proc Natl Acad Sci U S A (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, #2946)被用于被用于免疫印迹在人类样本上. Mutat Res (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(CellSignaling Technology, 2947)被用于被用于免疫印迹在人类样本上. Peerj (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类; 1:400; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫细胞化学在人类样本上浓度为1:400 (图 3). Oncotarget (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947 s)被用于被用于免疫印迹在人类样本上浓度为1:1000. J Exp Clin Cancer Res (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 6A
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在人类样本上 (图 6A). Cell Cycle (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫组化-石蜡切片; 小鼠; 图 9c
  • 免疫印迹; 人类; 1:1000; 图 4c
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 9c) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 4c). Nat Commun (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 1:500; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2946)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 5). Cancer Biol Ther (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠
赛信通(上海)生物试剂有限公司 p21抗体(Cst, 2947)被用于被用于免疫印迹在小鼠样本上. J Proteome Res (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Oncotarget (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2946)被用于被用于免疫印迹在人类样本上. Cell Death Differ (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 猕猴; 1:50; 图 s2a
赛信通(上海)生物试剂有限公司 p21抗体(Cell signaling, 12D1)被用于被用于免疫组化-石蜡切片在猕猴样本上浓度为1:50 (图 s2a). J Immunol (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. FEBS Lett (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:500; 图 5a
赛信通(上海)生物试剂有限公司 p21抗体(CST, 2947s)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 5a). Int J Clin Exp Med (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 大鼠; 1:1000; 图 9b
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在大鼠样本上浓度为1:1000 (图 9b). Int J Mol Med (2015) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹基因敲除验证; 人类; 图 1
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2946)被用于被用于免疫印迹基因敲除验证在人类样本上 (图 1). Proc Natl Acad Sci U S A (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化; 人类; 1:50
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫组化在人类样本上浓度为1:50. J Clin Endocrinol Metab (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:2000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:2000. Oncotarget (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5e
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 5e). Mol Cancer (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947S)被用于被用于免疫印迹在人类样本上. F1000Res (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000. Biochem Biophys Res Commun (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3). Cancer Res (2014) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 6
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2946)被用于被用于免疫印迹在人类样本上 (图 6). Oncogene (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 s3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在人类样本上 (图 s3). Proc Natl Acad Sci U S A (2014) ncbi
小鼠 单克隆(DCS60)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, DCS60)被用于被用于免疫印迹在人类样本上 (图 5). PLoS Genet (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947S)被用于被用于免疫印迹在人类样本上. Arch Pharm Res (2015) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上 (图 2). Cancer Biol Ther (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 流式细胞仪; 人类; 图 4
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, clone 12D1)被用于被用于流式细胞仪在人类样本上 (图 4). J Neurooncol (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. Mol Cell Biol (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. Oncogenesis (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. Cell Death Differ (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫沉淀在人类样本上 和 被用于免疫印迹在人类样本上. J Biol Chem (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上浓度为1:1000. FEBS J (2014) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. Redox Biol (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上. World J Gastroenterol (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠; 1:1000; 图 3
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 3). Nat Cell Biol (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上. Epigenetics (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上浓度为1:1000. Lab Invest (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 小鼠
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 12D1)被用于被用于免疫印迹在小鼠样本上. Mol Cancer Ther (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 12D1)被用于被用于免疫印迹在人类样本上 (图 5). Biochem J (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 2947)被用于被用于免疫印迹在人类样本上. Mol Oncol (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling, 2947)被用于被用于免疫印迹在人类样本上. PLoS ONE (2013) ncbi
domestic rabbit 单克隆(12D1)
  • 免疫组化-石蜡切片; 人类; 0.1 ug/ml
  • 免疫印迹; 人类; 1:1000
赛信通(上海)生物试剂有限公司 p21抗体(Cell Signaling Technology, 12D1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为0.1 ug/ml 和 被用于免疫印迹在人类样本上浓度为1:1000. Am J Pathol (2012) ncbi
丹科医疗器械技术服务(上海)有限公司
小鼠 单克隆(SX118)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 3
丹科医疗器械技术服务(上海)有限公司 p21抗体(DAKO, SX118)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 3). Endocr Pathol (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫组化; 人类; 1:150
丹科医疗器械技术服务(上海)有限公司 p21抗体(DAKO, SX118)被用于被用于免疫组化在人类样本上浓度为1:150. Int Urol Nephrol (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫组化-石蜡切片; 小鼠; 1:50; 图 1d
丹科医疗器械技术服务(上海)有限公司 p21抗体(DAKO, M7202)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:50 (图 1d). Clin Sci (Lond) (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类
丹科医疗器械技术服务(上海)有限公司 p21抗体(Dako, SX118)被用于被用于免疫印迹在人类样本上. Oncotarget (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫组化-石蜡切片; 人类; 1:1000; 表 3
丹科医疗器械技术服务(上海)有限公司 p21抗体(Dako, SX118)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:1000 (表 3). Am J Surg (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫组化-石蜡切片; 人类; 1:25
丹科医疗器械技术服务(上海)有限公司 p21抗体(Dako, clone SX118)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:25. Oral Dis (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 5
丹科医疗器械技术服务(上海)有限公司 p21抗体(Dako, M7202)被用于被用于免疫印迹在人类样本上 (图 5). Oncogenesis (2012) ncbi
碧迪BD
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 1:1000; 图 s5f
碧迪BD p21抗体(BD Biosciences, 556430)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 s5f). Cell Death Dis (2022) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化; 小鼠
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫组化在小鼠样本上. Cell Rep (2021) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠; 图 1e
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫印迹在小鼠样本上 (图 1e). Cell Death Discov (2021) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 1:2000; 图 2e
碧迪BD p21抗体(BD Pharmingen, 556,431)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 2e). Arch Toxicol (2021) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化; 小鼠; 1:1000; 图 s1h
碧迪BD p21抗体(BD, 556431)被用于被用于免疫组化在小鼠样本上浓度为1:1000 (图 s1h). Nature (2019) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-冰冻切片; 小鼠; 1:50; 图 1d
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫组化-冰冻切片在小鼠样本上浓度为1:50 (图 1d). elife (2019) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 1e
  • 免疫印迹; 人类; 1:1000; 图 1g
碧迪BD p21抗体(BD Pharmingen, PMG556431)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 1e) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 1g). EMBO J (2019) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 1:1000; 图 6f
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 6f). Stem Cell Reports (2019) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-石蜡切片; 小鼠; 1:50; 图 6c, s2d
碧迪BD p21抗体(BD Pharmingene, 556431)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:50 (图 6c, s2d). Sci Adv (2019) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 图 s1a
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫印迹在人类样本上 (图 s1a). Cell (2019) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 图 3e
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在小鼠样本上 (图 3e). Cell Death Dis (2018) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 6
碧迪BD p21抗体(BD, 556430)被用于被用于免疫印迹在人类样本上 (图 6). Oncotarget (2017) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 6a
碧迪BD p21抗体(BD Biosciences, 556430)被用于被用于免疫印迹在人类样本上 (图 6a). Cell Death Dis (2017) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-冰冻切片; 小鼠; 1:200; 图 3i
碧迪BD p21抗体(BD Pharmingen, SXM30)被用于被用于免疫组化-冰冻切片在小鼠样本上浓度为1:200 (图 3i). Genes Dev (2017) ncbi
小鼠 单克隆(SX118)
  • 免疫组化; 小鼠; 1:1000; 图 7h
  • 免疫印迹; 人类; 1:2000; 图 3g
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫组化在小鼠样本上浓度为1:1000 (图 7h) 和 被用于免疫印迹在人类样本上浓度为1:2000 (图 3g). Nat Commun (2017) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 图 1
碧迪BD p21抗体(BD Transduction Laboratories, 610233)被用于被用于免疫印迹在人类样本上 (图 1). Neuroendocrinology (2018) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠; 1:2000; 图 2a
碧迪BD p21抗体(BD Pharmingen, 556431)被用于被用于免疫印迹在小鼠样本上浓度为1:2000 (图 2a). Int J Cancer (2017) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 1:500; 图 2c
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 2c). Nat Commun (2016) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-石蜡切片; 小鼠; 图 6c
碧迪BD p21抗体(BD, 556431)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 6c). Nat Cell Biol (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 1:500; 图 6,7d
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 6,7d). Oncotarget (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 1
碧迪BD p21抗体(bD Bioscience, SX118)被用于被用于免疫印迹在人类样本上 (图 1). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化; 小鼠; 1:10; 图 s1
碧迪BD p21抗体(BD Bioscience, 556431)被用于被用于免疫组化在小鼠样本上浓度为1:10 (图 s1). Science (2016) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠; 图 1e
碧迪BD p21抗体(BD Pharmigen, 556431)被用于被用于免疫印迹在小鼠样本上 (图 1e). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 图 3
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在小鼠样本上 (图 3). Cell Rep (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 图 3
碧迪BD p21抗体(BD Bioscience, 556430)被用于被用于免疫印迹在小鼠样本上 (图 3). Sci Rep (2016) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠; 图 1
  • 免疫印迹; 人类; 图 1
碧迪BD p21抗体(BD Bioscience, 556431)被用于被用于免疫印迹在小鼠样本上 (图 1) 和 被用于免疫印迹在人类样本上 (图 1). Nat Commun (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 3a
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在人类样本上 (图 3a). PLoS ONE (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 图 s1
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在小鼠样本上 (图 s1). Cell Death Differ (2016) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 图 6
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫印迹在人类样本上 (图 6). Mol Cancer Ther (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 4e
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在人类样本上 (图 4e). Nat Commun (2016) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 图 1
碧迪BD p21抗体(BD, 610234)被用于被用于免疫印迹在人类样本上 (图 1). Oncogene (2016) ncbi
小鼠 单克隆(SX118)
  • 其他; 人类; 图 st1
碧迪BD p21抗体(BD, SX118)被用于被用于其他在人类样本上 (图 st1). Mol Cell Proteomics (2016) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠; 1:2000; 图 s4
碧迪BD p21抗体(BD Bioscience, 556431)被用于被用于免疫印迹在小鼠样本上浓度为1:2000 (图 s4). DNA Repair (Amst) (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 2
碧迪BD p21抗体(BD Biosciences, 556430)被用于被用于免疫印迹在人类样本上 (图 2). Redox Biol (2016) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 1:1000; 图 4b
碧迪BD p21抗体(BD Bioscience, 556430)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4b). Nat Commun (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 11
碧迪BD p21抗体(Pharmingen, 55643)被用于被用于免疫印迹在人类样本上 (图 11). J Biol Chem (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 图 11
碧迪BD p21抗体(Pharmingen, 55643)被用于被用于免疫印迹在人类样本上 (图 11). J Biol Chem (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 图 3d
碧迪BD p21抗体(BD Biosciences, 556431)被用于被用于免疫印迹在人类样本上 (图 3d). Oncotarget (2015) ncbi
  • 免疫印迹; 人类; 图 1
碧迪BD p21抗体(BD Biosciences, 550827)被用于被用于免疫印迹在人类样本上 (图 1). Autophagy (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 1:500
碧迪BD p21抗体(Pharmingen, 556431)被用于被用于免疫印迹在人类样本上浓度为1:500. Stem Cell Res (2015) ncbi
小鼠 单克隆(2G12)
  • 免疫印迹; 人类; 图 1
碧迪BD p21抗体(BD Pharmingen, 554262)被用于被用于免疫印迹在人类样本上 (图 1). Sci Rep (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 图 s3
碧迪BD p21抗体(BD, 556430)被用于被用于免疫印迹在小鼠样本上 (图 s3). J Cell Biol (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠; 1:2000; 图 3
碧迪BD p21抗体(BD, 556430)被用于被用于免疫印迹在小鼠样本上浓度为1:2000 (图 3). Nucleic Acids Res (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 1:1000; 图 1
碧迪BD p21抗体(BD PharMingen, 556431)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Cell Cycle (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类
碧迪BD p21抗体(BD Pharmingen, 556431)被用于被用于免疫印迹在人类样本上. Oncogene (2016) ncbi
小鼠 单克隆(2G12)
  • 免疫印迹; 人类; 图 2
碧迪BD p21抗体(BD Biosciences, 554262)被用于被用于免疫印迹在人类样本上 (图 2). Oncotarget (2015) ncbi
小鼠 单克隆(2G12)
  • 免疫印迹; 人类; 1:1000
碧迪BD p21抗体(BD Biosciences, 2G12)被用于被用于免疫印迹在人类样本上浓度为1:1000. J Surg Res (2015) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 图 5
碧迪BD p21抗体(BD Biosciences, 610233)被用于被用于免疫印迹在人类样本上 (图 5). PLoS ONE (2015) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 1:1000; 图 1
碧迪BD p21抗体(BD Biosciences, 610234)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1). Int J Oncol (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-石蜡切片; 小鼠; 1:200; 图 1
碧迪BD p21抗体(BD Pharmingen, 556431)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:200 (图 1). Mol Endocrinol (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠
碧迪BD p21抗体(BD Bioscience, SXM30)被用于被用于免疫印迹在小鼠样本上. Neoplasia (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫组化-石蜡切片; 小鼠; 1:50
碧迪BD p21抗体(BD Pharmingen, 556431)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:50. elife (2015) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 小鼠; 1:250; 图 1
  • 免疫印迹; 人类; 1:250; 图 1
碧迪BD p21抗体(BD Transduction laboratories, 610234)被用于被用于免疫印迹在小鼠样本上浓度为1:250 (图 1) 和 被用于免疫印迹在人类样本上浓度为1:250 (图 1). Oncotarget (2015) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类; 1:2000; 图 1
碧迪BD p21抗体(BD Pharmingen, 556431)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 1). Arch Toxicol (2016) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 1:100
碧迪BD p21抗体(BD Biosciences, 610234)被用于被用于免疫印迹在人类样本上浓度为1:100. J Radiat Res (2015) ncbi
小鼠 单克隆(6B6)
  • 免疫印迹; 人类; 1:500
碧迪BD p21抗体(BD Biosciences, 554228)被用于被用于免疫印迹在人类样本上浓度为1:500. J Endocrinol (2014) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类
碧迪BD p21抗体(BD, 556431)被用于被用于免疫印迹在人类样本上. Oncogene (2015) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类
碧迪BD p21抗体(BD Biosciences, 556430)被用于被用于免疫印迹在人类样本上. Mol Cell Biol (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 人类; 图 2
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在人类样本上 (图 2). Methods Mol Biol (2014) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类
碧迪BD p21抗体(BD Transduction Laboratories, 610233)被用于被用于免疫印迹在人类样本上. Biochem Biophys Res Commun (2014) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠; 图 6a
碧迪BD p21抗体(BD, 556431)被用于被用于免疫印迹在小鼠样本上 (图 6a). PLoS ONE (2014) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 大鼠; 1:1000
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在大鼠样本上浓度为1:1000. Biochim Biophys Acta (2014) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 1:1000
碧迪BD p21抗体(BD, 610233)被用于被用于免疫印迹在人类样本上浓度为1:1000. PLoS Pathog (2013) ncbi
小鼠 单克隆(SX118)
  • 免疫印迹; 小鼠
碧迪BD p21抗体(BD Pharmingen, 556430)被用于被用于免疫印迹在小鼠样本上. J Neurosci (2013) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 小鼠
碧迪BD p21抗体(BD Biosciences, SXM30)被用于被用于免疫印迹在小鼠样本上. Cell Death Differ (2013) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类; 图 6
碧迪BD p21抗体(BD Transduction Laboratories, 610233)被用于被用于免疫印迹在人类样本上 (图 6). Cell Cycle (2013) ncbi
小鼠 单克隆(70/Cip1/WAF1)
  • 免疫印迹; 人类
碧迪BD p21抗体(BD Biosciences, 610233)被用于被用于免疫印迹在人类样本上. Int J Cancer (2011) ncbi
小鼠 单克隆(SXM30)
  • 免疫印迹; 人类
碧迪BD p21抗体(BD Biosciences, SXM30)被用于被用于免疫印迹在人类样本上. Cell Death Differ (2008) ncbi
MBL International
单克隆
  • 免疫印迹; 人类; 图 2a
MBL International p21抗体(Medical and Biological Laboratories, K0081-3)被用于被用于免疫印迹在人类样本上 (图 2a). Sci Rep (2016) ncbi
单克隆
  • 免疫印迹; 人类; 图 1
MBL International p21抗体(MBL, K0081-3)被用于被用于免疫印迹在人类样本上 (图 1). J Biol Chem (2016) ncbi
徕卡显微系统(上海)贸易有限公司
  • 免疫组化-石蜡切片; 人类; 1:10; 图 5b
徕卡显微系统(上海)贸易有限公司 p21抗体(Leica Biosystems, NCL-L-WAF-1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:10 (图 5b). Nat Commun (2016) ncbi
文章列表
  1. Aboouf M, Armbruster J, Thiersch M, Guscetti F, Kristiansen G, Schraml P, et al. Pro-Apoptotic and Anti-Invasive Properties Underscore the Tumor-Suppressing Impact of Myoglobin on a Subset of Human Breast Cancer Cells. Int J Mol Sci. 2022;23: pubmed 出版商
  2. Fei X, Wu X, Dou Y, Sun K, Guo Q, Zhang L, et al. TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I. Mol Ther Oncolytics. 2022;26:413-428 pubmed 出版商
  3. Narayan S, Raza A, Mahmud I, Koo N, Garrett T, LAW M, et al. Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. iScience. 2022;25:104518 pubmed 出版商
  4. Mao L, Xin F, Ren J, Xu S, Huang H, Zha X, et al. 5-HT2B-mediated serotonin activation in enterocytes suppresses colitis-associated cancer initiation and promotes cancer progression. Theranostics. 2022;12:3928-3945 pubmed 出版商
  5. Chen J, Chen K, Wang L, Luo J, Zheng Q, He Y. Decoy receptor 2 mediates the apoptosis-resistant phenotype of senescent renal tubular cells and accelerates renal fibrosis in diabetic nephropathy. Cell Death Dis. 2022;13:522 pubmed 出版商
  6. Xing H, Gao M, Wang Y, Zhang X, Shi J, Wang X, et al. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma. Clin Transl Med. 2022;12:e835 pubmed 出版商
  7. Geng F, Yang W, Song D, Hou H, Han B, Chen Y, et al. MDIG, a 2‑oxoglutarate‑dependent oxygenase, acts as an oncogene and predicts the prognosis of multiple types of cancer. Int J Oncol. 2022;61: pubmed 出版商
  8. Jia F, Li H, Jiao Q, Li C, Fu L, Cui C, et al. Deubiquitylase OTUD3 prevents Parkinson's disease through stabilizing iron regulatory protein 2. Cell Death Dis. 2022;13:418 pubmed 出版商
  9. Yu J, Yang K, Zheng J, Zhao P, Xia J, Sun X, et al. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell Death Dis. 2022;13:388 pubmed 出版商
  10. Chen Z, Wu W, Zheng C, Lan Y, Xie H, Xie Z. KLF6 facilitates differentiation of odontoblasts through modulating the expression of P21 in vitro. Int J Oral Sci. 2022;14:20 pubmed 出版商
  11. Kidger A, Saville M, Rushworth L, Davidson J, Stellzig J, Ono M, et al. Suppression of mutant Kirsten-RAS (KRASG12D)-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6. Oncogene. 2022;41:2811-2823 pubmed 出版商
  12. Le A, Park S, Le M, Lee U, Ko B, Lim H, et al. DRG2 Depletion Promotes Endothelial Cell Senescence and Vascular Endothelial Dysfunction. Int J Mol Sci. 2022;23: pubmed 出版商
  13. Feng X, Guo J, An G, Wu Y, Liu Z, Meng B, et al. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma. Adv Sci (Weinh). 2022;9:e2104491 pubmed 出版商
  14. Chesnokova V, Zonis S, Apostolou A, Estrada H, Knott S, Wawrowsky K, et al. Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage. Cell Rep. 2021;37:110068 pubmed 出版商
  15. Xia R, Liu T, Li W, Xu X. RNA-binding protein RBM24 represses colorectal tumourigenesis by stabilising PTEN mRNA. Clin Transl Med. 2021;11:e383 pubmed 出版商
  16. Sáinz Jaspeado M, Smith R, Plunde O, Pawelzik S, Jin Y, Nordling S, et al. Palmdelphin Regulates Nuclear Resilience to Mechanical Stress in the Endothelium. Circulation. 2021;144:1629-1645 pubmed 出版商
  17. Chiang C, Hong Y. In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy. Sci Rep. 2021;11:18172 pubmed 出版商
  18. Lo Cascio C, McNamara J, Melendez E, Lewis E, Dufault M, Sanai N, et al. Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells. JCI Insight. 2021;6: pubmed 出版商
  19. Pratap U, Sareddy G, Liu Z, Venkata P, Liu J, Tang W, et al. Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. Neurooncol Adv. 2021;3:vdab099 pubmed 出版商
  20. Novais E, Tran V, Johnston S, Darris K, Roupas A, Sessions G, et al. Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat Commun. 2021;12:5213 pubmed 出版商
  21. Huang J, Xiao R, Wang X, Khadka B, Fang Z, Yu M, et al. MicroRNA‑93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2. Int J Oncol. 2021;59: pubmed 出版商
  22. Li T, Yang X, Xu D, Gao Z, Gao Y, Jin F, et al. OC-STAMP Overexpression Drives Lung Alveolar Epithelial Cell Type II Senescence in Silicosis. Oxid Med Cell Longev. 2021;2021:4158495 pubmed 出版商
  23. Gonzalez Rellan M, Fondevila M, Fernandez U, Rodríguez A, Varela Rey M, Veyrat Durebex C, et al. O-GlcNAcylated p53 in the liver modulates hepatic glucose production. Nat Commun. 2021;12:5068 pubmed 出版商
  24. Fan Z, Turiel G, Ardicoglu R, Ghobrial M, Masschelein E, Kocijan T, et al. Exercise-induced angiogenesis is dependent on metabolically primed ATF3/4+ endothelial cells. Cell Metab. 2021;: pubmed 出版商
  25. Kanellis D, Espinoza J, Zisi A, Sakkas E, Bartkova J, Katsori A, et al. The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Sci Adv. 2021;7: pubmed 出版商
  26. Lee J, Hong J, Zhang Z, de la Peña Avalos B, Proietti C, Deamicis A, et al. Regulation of telomere homeostasis and genomic stability in cancer by N 6-adenosine methylation (m6A). Sci Adv. 2021;7: pubmed 出版商
  27. Song L, Tian X, Schekman R. Extracellular vesicles from neurons promote neural induction of stem cells through cyclin D1. J Cell Biol. 2021;220: pubmed 出版商
  28. Prekovic S, Schuurman K, Mayayo Peralta I, Manjón A, Buijs M, Yavuz S, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nat Commun. 2021;12:4360 pubmed 出版商
  29. Urrutia G, de Assunção T, Mathison A, Salmonson A, Kerketta R, Zeighami A, et al. Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks. Front Cell Dev Biol. 2021;9:681153 pubmed 出版商
  30. Marquez Exposito L, Tejedor Santamaria L, Santos Sánchez L, Valentijn F, Cantero Navarro E, Rayego Mateos S, et al. Acute Kidney Injury is Aggravated in Aged Mice by the Exacerbation of Proinflammatory Processes. Front Pharmacol. 2021;12:662020 pubmed 出版商
  31. Chronowski C, Akhanov V, CHAN D, Catic A, Finegold M, Sahin E. Fructose Causes Liver Damage, Polyploidy, and Dysplasia in the Setting of Short Telomeres and p53 Loss. Metabolites. 2021;11: pubmed 出版商
  32. Sakai H, Kawakami H, Teramura T, Onodera Y, Somers E, Furuuchi K, et al. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. Clin Transl Med. 2021;11:e454 pubmed 出版商
  33. Bailey K, Cartwright S, Patel N, Remmers N, Lazenby A, Hollingsworth M, et al. Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic. Sci Rep. 2021;11:13436 pubmed 出版商
  34. Zhang Y, Hu M, Yang F, Zhang Y, Ma S, Zhang D, et al. Increased uterine androgen receptor protein abundance results in implantation and mitochondrial defects in pregnant rats with hyperandrogenism and insulin resistance. J Mol Med (Berl). 2021;99:1427-1446 pubmed 出版商
  35. Bloniarz D, Adamczyk Grochala J, Lewinska A, Wnuk M. The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence. Aging (Albany NY). 2021;13:15833-15874 pubmed 出版商
  36. Yuan Y, Cao W, Zhou H, Qian H, Wang H. H2A.Z acetylation by lincZNF337-AS1 via KAT5 implicated in the transcriptional misregulation in cancer signaling pathway in hepatocellular carcinoma. Cell Death Dis. 2021;12:609 pubmed 出版商
  37. Lee H, Donati A, Feliers D, Sun Y, Ding Y, Madesh M, et al. Chloride channel accessory 1 integrates chloride channel activity and mTORC1 in aging-related kidney injury. Aging Cell. 2021;20:e13407 pubmed 出版商
  38. Gan L, Liu D, Liu J, Chen E, Chen C, Liu L, et al. CD38 deficiency alleviates Ang II-induced vascular remodeling by inhibiting small extracellular vesicle-mediated vascular smooth muscle cell senescence in mice. Signal Transduct Target Ther. 2021;6:223 pubmed 出版商
  39. Wang R, Yang D, Liu Y, Ding J, Guo Y, Ding W, et al. Cell cycle exit and neuronal differentiation 1-engineered embryonic neural stem cells enhance neuronal differentiation and neurobehavioral recovery after experimental traumatic brain injury. Neural Regen Res. 2022;17:130-136 pubmed 出版商
  40. Lai W, Zhu W, Xiao C, Li X, Wang Y, Han Y, et al. HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway. Cell Death Dis. 2021;12:583 pubmed 出版商
  41. Sanchez Rivera F, Ryan J, Soto Feliciano Y, Clare Beytagh M, Xuan L, Feldser D, et al. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc Natl Acad Sci U S A. 2021;118: pubmed 出版商
  42. Kim C, Jin J, Ye Z, Jadhav R, Gustafson C, Hu B, et al. Histone deficiency and accelerated replication stress in T cell aging. J Clin Invest. 2021;131: pubmed 出版商
  43. Yang S, Hollingshead M, Rubinstein L, Nguyen D, Larenjeira A, Kinders R, et al. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models. J Hematol Oncol. 2021;14:83 pubmed 出版商
  44. Niu B, Liu J, Lv B, Lin J, Li X, Wu C, et al. Interplay between transforming growth factor-β and Nur77 in dual regulations of inhibitor of differentiation 1 for colonic tumorigenesis. Nat Commun. 2021;12:2809 pubmed 出版商
  45. Huang P, Bai L, Liu L, Fu J, Wu K, Liu H, et al. Redd1 knockdown prevents doxorubicin-induced cardiac senescence. Aging (Albany NY). 2021;13:13788-13806 pubmed 出版商
  46. Pettinato A, Yoo D, VanOudenhove J, Chen Y, Cohn R, Ladha F, et al. Sarcomere function activates a p53-dependent DNA damage response that promotes polyploidization and limits in vivo cell engraftment. Cell Rep. 2021;35:109088 pubmed 出版商
  47. Morimune T, Tano A, Tanaka Y, Yukiue H, Yamamoto T, Tooyama I, et al. Gm14230 controls Tbc1d24 cytoophidia and neuronal cellular juvenescence. PLoS ONE. 2021;16:e0248517 pubmed 出版商
  48. Li W, Zheng J, Zhao G, Lyu C, Lu W. Overexpression of DSCR1 prevents proliferation and predicts favorable prognosis in colorectal cancer patients. World J Surg Oncol. 2021;19:100 pubmed 出版商
  49. Lee S, Park K, Lee G, Kim S, Song W, Kwon S, et al. Hypoxia-inducible factor-2α mediates senescence-associated intrinsic mechanisms of age-related bone loss. Exp Mol Med. 2021;53:591-604 pubmed 出版商
  50. Plácido L, Romero Y, Maldonado M, Toscano Marquez F, Ramirez R, Calyeca J, et al. Loss of MT1-MMP in Alveolar Epithelial Cells Exacerbates Pulmonary Fibrosis. Int J Mol Sci. 2021;22: pubmed 出版商
  51. Shi L, Magee P, Fassan M, Sahoo S, Leong H, LEE D, et al. A KRAS-responsive long non-coding RNA controls microRNA processing. Nat Commun. 2021;12:2038 pubmed 出版商
  52. Nishad R, Mukhi D, Singh A, Motrapu M, Chintala K, Tammineni P, et al. Growth hormone induces mitotic catastrophe of glomerular podocytes and contributes to proteinuria. Cell Death Dis. 2021;12:342 pubmed 出版商
  53. Dong C, Jiang T, Yin H, Song H, Zhang Y, Geng H, et al. LMNB2 promotes the progression of colorectal cancer by silencing p21 expression. Cell Death Dis. 2021;12:331 pubmed 出版商
  54. Xia X, Huang C, Liao Y, Liu Y, He J, Shao Z, et al. The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression. Cell Death Dis. 2021;12:329 pubmed 出版商
  55. Lagnado A, Leslie J, Ruchaud Sparagano M, Victorelli S, Hirsova P, Ogrodnik M, et al. Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. EMBO J. 2021;40:e106048 pubmed 出版商
  56. Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, et al. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ. 2021;28:2450-2464 pubmed 出版商
  57. Goncalves S, Yin K, Ito Y, Chan A, Olan I, Gough S, et al. COX2 regulates senescence secretome composition and senescence surveillance through PGE2. Cell Rep. 2021;34:108860 pubmed 出版商
  58. Xue Y, Chen H, Zhang S, Bao L, Chen B, Gong H, et al. Resveratrol Confers Vascular Protection by Suppressing TLR4/Syk/NLRP3 Signaling in Oxidized Low-Density Lipoprotein-Activated Platelets. Oxid Med Cell Longev. 2021;2021:8819231 pubmed 出版商
  59. Nagamura Y, Miyazaki M, Nagano Y, Yuki M, Fukami K, Yanagihara K, et al. PLEKHA5 regulates the survival and peritoneal dissemination of diffuse-type gastric carcinoma cells with Met gene amplification. Oncogenesis. 2021;10:25 pubmed 出版商
  60. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, et al. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021;23:29 pubmed 出版商
  61. Bressan R, Southgate B, Ferguson K, Blin C, Grant V, Alfazema N, et al. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants. Cell Stem Cell. 2021;28:877-893.e9 pubmed 出版商
  62. Kumar B, Ahmad R, Giannico G, Zent R, Talmon G, Harris R, et al. Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation. J Exp Clin Cancer Res. 2021;40:77 pubmed 出版商
  63. Chen J, Xu D, Cao J, Zuo L, Han Z, Tian Y, et al. TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination. Cancer Cell Int. 2021;21:129 pubmed 出版商
  64. Su S, Li Q, Zhang M, Zhang P, Shen H, Zhang C. An E2F1/DDX11/EZH2 Positive Feedback Loop Promotes Cell Proliferation in Hepatocellular Carcinoma. Front Oncol. 2020;10:593293 pubmed 出版商
  65. Innes A, Sun B, Wagner V, Brookes S, McHugh D, Pombo J, et al. XPO7 is a tumor suppressor regulating p21CIP1-dependent senescence. Genes Dev. 2021;35:379-391 pubmed 出版商
  66. Dufeys C, Daskalopoulos E, Castanares Zapatero D, Conway S, Ginion A, Bouzin C, et al. AMPKα1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism. Basic Res Cardiol. 2021;116:10 pubmed 出版商
  67. Lee J, Park I, Kwak M, Rhee W, Kim S, Shin J. HMGB1 orchestrates STING-mediated senescence via TRIM30α modulation in cancer cells. Cell Death Discov. 2021;7:28 pubmed 出版商
  68. Buj R, Leon K, Anguelov M, Aird K. Suppression of p16 alleviates the senescence-associated secretory phenotype. Aging (Albany NY). 2021;13:3290-3312 pubmed 出版商
  69. Tyler E, Gutierrez Del Arroyo A, Hughes B, Wallis R, Garbe J, Stampfer M, et al. Early growth response 2 (EGR2) is a novel regulator of the senescence programme. Aging Cell. 2021;20:e13318 pubmed 出版商
  70. Kim B, Ryu K, Lee S, Kim T. Changes in telomere length and senescence markers during human ovarian tissue cryopreservation. Sci Rep. 2021;11:2238 pubmed 出版商
  71. Ghonim M, Ibba S, Tarhuni A, Errami Y, Luu H, Dean M, et al. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer. 2021;9: pubmed 出版商
  72. Rothmiller S, Jäger N, Meier N, Meyer T, Neu A, Steinritz D, et al. Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021;95:727-747 pubmed 出版商
  73. Buitrago Molina L, Marhenke S, Becker D, Geffers R, Itzel T, Teufel A, et al. p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. Cell Mol Gastroenterol Hepatol. 2021;11:1387-1404 pubmed 出版商
  74. Li R, Li Y, Qin H, Li S. ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes. Onco Targets Ther. 2021;14:199-211 pubmed 出版商
  75. Chibaya L, Karim B, Zhang H, Jones S. Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis. Proc Natl Acad Sci U S A. 2021;118: pubmed 出版商
  76. Peng D, Lin B, Xie M, Zhang P, Guo Q, Li Q, et al. Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor. Cell Death Discov. 2021;7:9 pubmed 出版商
  77. Jiang Y, Xiang C, Zhong F, Zhang Y, Wang L, Zhao Y, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Theranostics. 2021;11:361-378 pubmed 出版商
  78. Reedich E, Kalski M, Armijo N, Cox G, DiDonato C. Spinal motor neuron loss occurs through a p53-and-p21-independent mechanism in the Smn2B/- mouse model of spinal muscular atrophy. Exp Neurol. 2021;337:113587 pubmed 出版商
  79. Dewhurst M, Ow J, Zafer G, Van Hul N, Wollmann H, Bisteau X, et al. Loss of hepatocyte cell division leads to liver inflammation and fibrosis. PLoS Genet. 2020;16:e1009084 pubmed 出版商
  80. Chen H, Lo C, Huang C, Lu M, Hu P, Chen C, et al. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis. J Clin Invest. 2021;131: pubmed 出版商
  81. Cai J, Lin K, Cai W, Lin Y, Liu X, Guo L, et al. Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Mol Oncol. 2020;14:3153-3168 pubmed 出版商
  82. Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C, He T, et al. Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis. Cancer Res Treat. 2021;53:184-198 pubmed 出版商
  83. Wueest S, Lucchini F, Haim Y, Rudich A, Konrad D. Depletion of ASK1 blunts stress-induced senescence in adipocytes. Adipocyte. 2020;9:535-541 pubmed 出版商
  84. Zatulovskiy E, Zhang S, Berenson D, Topacio B, Skotheim J. Cell growth dilutes the cell cycle inhibitor Rb to trigger cell division. Science. 2020;369:466-471 pubmed 出版商
  85. Osei Amponsa V, Sridharan V, Tandon M, Evans C, Klarmann K, Cheng K, et al. Impact of losing hRpn13 Pru or UCHL5 on proteasome clearance of ubiquitinated proteins and RA190 cytotoxicity. Mol Cell Biol. 2020;: pubmed 出版商
  86. Hu D, Dong R, Zhang Y, Yang Y, Chen Z, Tang Y, et al. Age‑related changes in mineralocorticoid receptors in rat hearts. Mol Med Rep. 2020;22:1859-1867 pubmed 出版商
  87. Hastings J, González Rajal A, Latham S, Han J, McCloy R, O Donnell Y, et al. Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. elife. 2020;9: pubmed 出版商
  88. Hu H, Ji Q, Song M, Ren J, Liu Z, Wang Z, et al. ZKSCAN3 counteracts cellular senescence by stabilizing heterochromatin. Nucleic Acids Res. 2020;48:6001-6018 pubmed 出版商
  89. Wu P, Hong S, Starenki D, Oshima K, Shao H, Gestwicki J, et al. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene. 2020;39:4257-4270 pubmed 出版商
  90. Lochab S, Singh Y, Sengupta S, Nandicoori V. Mycobacterium tuberculosis exploits host ATM kinase for survival advantage through SecA2 secretome. elife. 2020;9: pubmed 出版商
  91. Zhang J, Huang J, Zhang Y, Zhang X, Zhao L, Li C, et al. Microtubule associated protein 9 inhibits liver tumorigenesis by suppressing ERCC3. EBioMedicine. 2020;53:102701 pubmed 出版商
  92. Zang M, Guo J, Liu L, Jin F, Feng X, An G, et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis. 2020;9:31 pubmed 出版商
  93. Lin Y, Huang X, Chang K, Liao K, Tsai N. Encapsulated n-Butylidenephthalide Efficiently Crosses the Blood-Brain Barrier and Suppresses Growth of Glioblastoma. Int J Nanomedicine. 2020;15:749-760 pubmed 出版商
  94. Pothuraju R, Rachagani S, Krishn S, Chaudhary S, Nimmakayala R, Siddiqui J, et al. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. Mol Cancer. 2020;19:37 pubmed 出版商
  95. Zhao Z, Wang Y, Yun D, Huang Q, Meng D, Li Q, et al. TRIM21 overexpression promotes tumor progression by regulating cell proliferation, cell migration and cell senescence in human glioma. Am J Cancer Res. 2020;10:114-130 pubmed
  96. Huang S, Zhang C, Sun C, Hou Y, Zhang Y, Tam N, et al. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. Aging (Albany NY). 2020;12:3025-3041 pubmed 出版商
  97. Lo M, Damon L, Wei Tay J, Jia S, Palmer A. Single cell analysis reveals multiple requirements for zinc in the mammalian cell cycle. elife. 2020;9: pubmed 出版商
  98. Cui J, Duan J, Chu J, Guo C, Xi M, Li Y, et al. Chikusetsu saponin IVa protects pancreatic β cell against intermittent high glucose-induced injury by activating Wnt/β-catenin/TCF7L2 pathway. Aging (Albany NY). 2020;12:1591-1609 pubmed 出版商
  99. Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12:1272-1284 pubmed 出版商
  100. Cassidy L, Young A, Young C, Soilleux E, Fielder E, Weigand B, et al. Temporal inhibition of autophagy reveals segmental reversal of ageing with increased cancer risk. Nat Commun. 2020;11:307 pubmed 出版商
  101. Aldaz P, Otaegi Ugartemendia M, Sáenz Antoñanzas A, Garcia Puga M, Moreno Valladares M, Flores J, et al. SOX9 promotes tumor progression through the axis BMI1-p21CIP. Sci Rep. 2020;10:357 pubmed 出版商
  102. Xue J, Zhao Y, Aronowitz J, Mai T, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421-425 pubmed 出版商
  103. Li B, Li M, Li X, Li H, Lai Y, Huang S, et al. Sirt1-inducible deacetylation of p21 promotes cardiomyocyte proliferation. Aging (Albany NY). 2019;11:12546-12567 pubmed 出版商
  104. Tang L, Li J, Fu W, Wu W, Xu J. Suppression of FADS1 induces ROS generation, cell cycle arrest, and apoptosis in melanocytes: implications for vitiligo. Aging (Albany NY). 2019;11:11829-11843 pubmed 出版商
  105. Wang H, Chen Z, Wang S, Gao X, Qian M, Qiu W, et al. TGFβ1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-κB signalling pathway in human gliomas. Mol Oncol. 2020;14:407-425 pubmed 出版商
  106. Guiley K, Stevenson J, Lou K, Barkovich K, Kumarasamy V, Wijeratne T, et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 2019;366: pubmed 出版商
  107. Xu S, Zhan M, Jiang C, He M, Yang L, Shen H, et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun. 2019;10:5492 pubmed 出版商
  108. Ko H, Hwang I, Jin E, Yun T, Ryu D, Kang J, et al. Roles of ErbB3-binding protein 1 (EBP1) in embryonic development and gene-silencing control. Proc Natl Acad Sci U S A. 2019;116:24852-24860 pubmed 出版商
  109. Veschi V, Mangiapane L, Nicotra A, Di Franco S, Scavo E, Apuzzo T, et al. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene. 2020;39:987-1003 pubmed 出版商
  110. Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019;: pubmed 出版商
  111. Riessland M, Kolisnyk B, Kim T, Cheng J, Ni J, Pearson J, et al. Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons. Cell Stem Cell. 2019;25:514-530.e8 pubmed 出版商
  112. Morris J, Yashinskie J, Koche R, Chandwani R, Tian S, Chen C, et al. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature. 2019;573:595-599 pubmed 出版商
  113. Liu G, Zhang Q, Xia L, Shi M, Cai J, Zhang H, et al. RNA-binding protein CELF6 is cell cycle regulated and controls cancer cell proliferation by stabilizing p21. Cell Death Dis. 2019;10:688 pubmed 出版商
  114. McMahon M, Contreras A, Holm M, Uechi T, Forester C, Pang X, et al. A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS. elife. 2019;8: pubmed 出版商
  115. Diaz Osterman C, Ozmadenci D, Kleinschmidt E, Taylor K, Barrie A, Jiang S, et al. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. elife. 2019;8: pubmed 出版商
  116. Thangaraj K, Balasubramanian B, Park S, Natesan K, Liu W, Manju V. Orientin Induces G0/G1 Cell Cycle Arrest and Mitochondria Mediated Intrinsic Apoptosis in Human Colorectal Carcinoma HT29 Cells. Biomolecules. 2019;9: pubmed 出版商
  117. Ji M, Wang Z, Chen J, Gu L, Chen M, Ding Y, et al. Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating β-catenin. Biosci Rep. 2019;39: pubmed 出版商
  118. Gal H, Lysenko M, Stroganov S, Vadai E, Youssef S, Tzadikevitch Geffen K, et al. Molecular pathways of senescence regulate placental structure and function. EMBO J. 2019;38:e100849 pubmed 出版商
  119. Gao X, Chen H, Liu J, Shen S, Wang Q, Clement T, et al. The REGγ-Proteasome Regulates Spermatogenesis Partially by P53-PLZF Signaling. Stem Cell Reports. 2019;13:559-571 pubmed 出版商
  120. Boettcher S, Miller P, Sharma R, McConkey M, Leventhal M, Krivtsov A, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599-604 pubmed 出版商
  121. Sin Chan P, Mumal I, Suwal T, Ho B, Fan X, Singh I, et al. A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 2019;36:51-67.e7 pubmed 出版商
  122. Xie X, Wang Y, Xia Y, Mao Y. Overexpressed vascular endothelial growth factor in adipose derived stem cells attenuates fibroblasts and skin injuries by ultraviolet radiation. Biosci Rep. 2019;39: pubmed 出版商
  123. Kaur S, Nag A, Gangenahalli G, Sharma K. Peroxisome Proliferator Activated Receptor Gamma Sensitizes Non-small Cell Lung Carcinoma to Gamma Irradiation Induced Apoptosis. Front Genet. 2019;10:554 pubmed 出版商
  124. Minuesa G, Albanese S, Xie W, Kazansky Y, Worroll D, Chow A, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 2019;10:2691 pubmed 出版商
  125. Hsu C, Altschuler S, Wu L. Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy. Cell. 2019;: pubmed 出版商
  126. Hari P, Millar F, Tarrats N, Birch J, Quintanilla A, Rink C, et al. The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype. Sci Adv. 2019;5:eaaw0254 pubmed 出版商
  127. Luo X, Jiang X, Li J, Bai Y, Li Z, Wei P, et al. Insulin-like growth factor-1 attenuates oxidative stress-induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53-progerin interaction. Cell Death Dis. 2019;10:451 pubmed 出版商
  128. Bigot N, Day M, Baldock R, Watts F, Oliver A, Pearl L. Phosphorylation-mediated interactions with TOPBP1 couple 53BP1 and 9-1-1 to control the G1 DNA damage checkpoint. elife. 2019;8: pubmed 出版商
  129. Choi J, Zhong X, McAlpine W, Liao T, Zhang D, Fang B, et al. LMBR1L regulates lymphopoiesis through Wnt/β-catenin signaling. Science. 2019;364: pubmed 出版商
  130. Liu X, Zhao P, Wang X, Wang L, Zhu Y, Song Y, et al. Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells. J Exp Clin Cancer Res. 2019;38:184 pubmed 出版商
  131. Kucab J, Zou X, Morganella S, Joel M, Nanda A, Nagy E, et al. A Compendium of Mutational Signatures of Environmental Agents. Cell. 2019;177:821-836.e16 pubmed 出版商
  132. Chan E, Shibue T, McFarland J, Gaeta B, Ghandi M, Dumont N, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568:551-556 pubmed 出版商
  133. Gao L, Hu Y, Tian Y, Fan Z, Wang K, Li H, et al. Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Nat Commun. 2019;10:1665 pubmed 出版商
  134. Fu L, Hu Y, Song M, Liu Z, Zhang W, Yu F, et al. Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis. PLoS Biol. 2019;17:e3000201 pubmed 出版商
  135. Ao Y, Zhang J, Liu Z, Qian M, Li Y, Wu Z, et al. Lamin A buffers CK2 kinase activity to modulate aging in a progeria mouse model. Sci Adv. 2019;5:eaav5078 pubmed 出版商
  136. Pillay N, Tighe A, Nelson L, Littler S, Coulson Gilmer C, Bah N, et al. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. Cancer Cell. 2019;35:519-533.e8 pubmed 出版商
  137. Cornell L, Wander S, Visal T, Wagle N, Shapiro G. MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Rep. 2019;26:2667-2680.e7 pubmed 出版商
  138. Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roche H, et al. Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death Dis. 2019;10:199 pubmed 出版商
  139. Zhang X, Qin Q, Dai H, Cai S, Zhou C, Guan J. Emodin protects H9c2 cells from hypoxia-induced injury by up-regulating miR-138 expression. Braz J Med Biol Res. 2019;52:e7994 pubmed 出版商
  140. Feng F, Wang Z, Li R, Wu Q, Gu C, Xu Y, et al. Citrus alkaline extracts prevent fibroblast senescence to ameliorate pulmonary fibrosis via activation of COX-2. Biomed Pharmacother. 2019;112:108669 pubmed 出版商
  141. Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019;38: pubmed 出版商
  142. Gronke K, Hernandez P, Zimmermann J, Klose C, Kofoed Branzk M, Guendel F, et al. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019;566:249-253 pubmed 出版商
  143. Wu Y, Li X, Yu J, Bjorkholm M, Xu D. ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells. Cell Death Dis. 2019;10:76 pubmed 出版商
  144. Nassour J, Radford R, Correia A, Fusté J, Schoell B, Jauch A, et al. Autophagic cell death restricts chromosomal instability during replicative crisis. Nature. 2019;565:659-663 pubmed 出版商
  145. Ren D, Dai Y, Yang Q, Zhang X, Guo W, Ye L, et al. Wnt5a induces and maintains prostate cancer cells dormancy in bone. J Exp Med. 2019;216:428-449 pubmed 出版商
  146. Zhao Z, Wang L, Volk A, Birch N, Stoltz K, Bartom E, et al. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia. Genes Dev. 2019;33:61-74 pubmed 出版商
  147. Mohni K, Wessel S, Zhao R, Wojciechowski A, Luzwick J, Layden H, et al. HMCES Maintains Genome Integrity by Shielding Abasic Sites in Single-Strand DNA. Cell. 2019;176:144-153.e13 pubmed 出版商
  148. Wang Y, Du L, Liang X, Meng P, Bi L, Wang Y, et al. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. Hepatology. 2018;: pubmed 出版商
  149. Peng J, Liang S, Li L. sFRP1 exerts effects on gastric cancer cells through GSK3β/Rac1‑mediated restraint of TGFβ/Smad3 signaling. Oncol Rep. 2019;41:224-234 pubmed 出版商
  150. Russell J, Lu W, Okabe H, Abrams M, Oertel M, Poddar M, et al. Hepatocyte-Specific β-Catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate Into Hepatocytes. Hepatology. 2019;69:742-759 pubmed 出版商
  151. Matyskiela M, Couto S, Zheng X, Lu G, Hui J, Stamp K, et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat Chem Biol. 2018;14:981-987 pubmed 出版商
  152. Zhang Y, Wang J, Huang W, Cai J, Ba J, Wang Y, et al. Nuclear Nestin deficiency drives tumor senescence via lamin A/C-dependent nuclear deformation. Nat Commun. 2018;9:3613 pubmed 出版商
  153. Wang L, Wang J, Jin T, Zhou Y, Chen Q. FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma. Biochem Biophys Res Commun. 2018;504:46-53 pubmed 出版商
  154. Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya M, Wang X, et al. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. J Clin Invest. 2018;128:4924-4937 pubmed 出版商
  155. Kim S, Jin H, Seo H, Lee H, Lee Y. Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation. Cell Death Differ. 2019;26:812-825 pubmed 出版商
  156. Bernal A, Moltó Abad M, Dominguez D, Tusell L. Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16INK4a-deficient epithelial cells. Oncotarget. 2018;9:27151-27170 pubmed 出版商
  157. Ng S, Yoshida N, Christie A, Ghandi M, Dharia N, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024 pubmed 出版商
  158. Jin L, Lu J, Gao J. Silencing SUMO2 promotes protection against degradation and apoptosis of nucleus pulposus cells through p53 signaling pathway in intervertebral disc degeneration. Biosci Rep. 2018;38: pubmed 出版商
  159. Xu B, Deng Y, Bi R, Guo H, Shu C, Shah N, et al. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification. Cancer Chemother Pharmacol. 2018;81:1083-1093 pubmed 出版商
  160. Morgan E, Wasson C, Hanson L, Kealy D, Pentland I, McGuire V, et al. STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle. PLoS Pathog. 2018;14:e1006975 pubmed 出版商
  161. Ghosh R, Roy S, Franco S. PARP1 depletion induces RIG-I-dependent signaling in human cancer cells. PLoS ONE. 2018;13:e0194611 pubmed 出版商
  162. Lee C, Hsieh T. Wuho/WDR4 deficiency inhibits cell proliferation and induces apoptosis via DNA damage in mouse embryonic fibroblasts. Cell Signal. 2018;47:16-26 pubmed 出版商
  163. Galanos P, Pappas G, Polyzos A, Kotsinas A, Svolaki I, Giakoumakis N, et al. Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. Genome Biol. 2018;19:37 pubmed 出版商
  164. Le Duff M, Gouju J, Jonchère B, Guillon J, Toutain B, Boissard A, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. Cell Death Dis. 2018;9:199 pubmed 出版商
  165. Zhao Y, Tan M, Liu X, Xiong X, Sun Y. Inactivation of ribosomal protein S27-like confers radiosensitivity via the Mdm2-p53 and Mdm2-MRN-ATM axes. Cell Death Dis. 2018;9:145 pubmed 出版商
  166. Chen K, Dai H, Yuan J, Chen J, Lin L, Zhang W, et al. Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy. Cell Death Dis. 2018;9:105 pubmed 出版商
  167. Shen L, Qu X, Li H, Xu C, Wei M, Wang Q, et al. NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis. Oncogene. 2018;37:1759-1774 pubmed 出版商
  168. Wu X, Dao Thi V, Huang Y, Billerbeck E, Saha D, Hoffmann H, et al. Intrinsic Immunity Shapes Viral Resistance of Stem Cells. Cell. 2018;172:423-438.e25 pubmed 出版商
  169. Sorokina I, Denisenko T, Imreh G, Tyurin Kuzmin P, Kaminskyy V, Gogvadze V, et al. Involvement of autophagy in the outcome of mitotic catastrophe. Sci Rep. 2017;7:14571 pubmed 出版商
  170. Zheng X, Dong Q, Zhang X, Han Q, Han X, Han Y, et al. The coiled-coil domain of oncogene RASSF 7 inhibits hippo signaling and promotes non-small cell lung cancer. Oncotarget. 2017;8:78734-78748 pubmed 出版商
  171. Zhao X, Huang L, Xu W, Chen X, Shen Y, Zeng W, et al. Physapubescin B inhibits tumorgenesis and circumvents taxol resistance of ovarian cancer cells through STAT3 signaling. Oncotarget. 2017;8:70130-70141 pubmed 出版商
  172. Zhao Z, Jia Q, Wu M, Xie X, Wang Y, Song G, et al. Degalactotigonin, a Natural Compound from Solanum nigrum L., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation-Mediated Repression of the Hedgehog/Gli1 Pathway. Clin Cancer Res. 2018;24:130-144 pubmed 出版商
  173. Nakagawa N, Li J, Yabuno Nakagawa K, Eom T, Cowles M, Mapp T, et al. APC sets the Wnt tone necessary for cerebral cortical progenitor development. Genes Dev. 2017;31:1679-1692 pubmed 出版商
  174. Haricharan S, Punturi N, Singh P, Holloway K, Anurag M, Schmelz J, et al. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017;7:1168-1183 pubmed 出版商
  175. Zhou Y, Huang T, Zhang J, Wong C, Zhang B, Dong Y, et al. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene. 2017;36:6518-6530 pubmed 出版商
  176. Azimzadeh O, Subramanian V, Ständer S, Merl Pham J, Lowe D, Barjaktarovic Z, et al. Proteome analysis of irradiated endothelial cells reveals persistent alteration in protein degradation and the RhoGDI and NO signalling pathways. Int J Radiat Biol. 2017;93:920-928 pubmed 出版商
  177. Patel N, Garikapati K, Pandita R, Singh D, Pandita T, Bhadra U, et al. miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin. Sci Rep. 2017;7:4263 pubmed 出版商
  178. Hsu J, Hubbell Engler B, Adelmant G, Huang J, Joyce C, Vazquez F, et al. PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res. 2017;77:4613-4625 pubmed 出版商
  179. Chavali P, Stojic L, Meredith L, Joseph N, Nahorski M, Sanford T, et al. Neurodevelopmental protein Musashi-1 interacts with the Zika genome and promotes viral replication. Science. 2017;357:83-88 pubmed 出版商
  180. He D, Ren B, Liu S, Tan L, Cieply K, Tseng G, et al. Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies. Oncogene. 2017;36:3629-3639 pubmed 出版商
  181. Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Oncotarget. 2017;8:30908-30921 pubmed 出版商
  182. Sun J, Zhang X, Sun Y, Tang Z, Guo D. Effects of Hylomecon vernalis ethanol extracts on cell cycle and apoptosis of colon cancer cells. Mol Med Rep. 2017;15:3485-3492 pubmed 出版商
  183. Mytych J, Romerowicz Misielak M, Koziorowski M. Long-term culture with lipopolysaccharide induces dose-dependent cytostatic and cytotoxic effects in THP-1 monocytes. Toxicol In Vitro. 2017;42:1-9 pubmed 出版商
  184. Yu G, Zhang T, Jing Y, Bao Q, Tang Q, Zhang Y. miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. Life Sci. 2017;175:47-51 pubmed 出版商
  185. Coni S, Mancuso A, Di Magno L, Sdruscia G, Manni S, Serrao S, et al. Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Sci Rep. 2017;7:44079 pubmed 出版商
  186. Xu P, Zhou Z, Xiong M, Zou W, Deng X, Ganaie S, et al. Parvovirus B19 NS1 protein induces cell cycle arrest at G2-phase by activating the ATR-CDC25C-CDK1 pathway. PLoS Pathog. 2017;13:e1006266 pubmed 出版商
  187. Teveroni E, Pellegrino M, Sacconi S, Calandra P, Cascino I, Farioli Vecchioli S, et al. Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. J Clin Invest. 2017;127:1531-1545 pubmed 出版商
  188. Xu J, Wu Y, Lu G, Xie S, Ma Z, Chen Z, et al. Importance of ROS-mediated autophagy in determining apoptotic cell death induced by physapubescin B. Redox Biol. 2017;12:198-207 pubmed 出版商
  189. Barilari M, Bonfils G, Treins C, Koka V, De Villeneuve D, Fabrega S, et al. ZRF1 is a novel S6 kinase substrate that drives the senescence programme. EMBO J. 2017;36:736-750 pubmed 出版商
  190. Yuan H, Tan B, Gao S. Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis. 2017;8:e2608 pubmed 出版商
  191. Li G, Ji T, Chen J, Fu Y, Hou L, Feng Y, et al. CRL4DCAF8 Ubiquitin Ligase Targets Histone H3K79 and Promotes H3K9 Methylation in the Liver. Cell Rep. 2017;18:1499-1511 pubmed 出版商
  192. Tormos A, Rius Pérez S, Jorques M, Rada P, Ramírez L, Valverde A, et al. p38α regulates actin cytoskeleton and cytokinesis in hepatocytes during development and aging. PLoS ONE. 2017;12:e0171738 pubmed 出版商
  193. Vendetti F, Leibowitz B, Barnes J, Schamus S, Kiesel B, Abberbock S, et al. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep. 2017;7:41892 pubmed 出版商
  194. Ritschka B, Storer M, Mas A, Heinzmann F, Ortells M, Morton J, et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 2017;31:172-183 pubmed 出版商
  195. Xiang J, Yang S, Xin N, Gaertig M, Reeves R, Li S, et al. DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome. Proc Natl Acad Sci U S A. 2017;114:E1224-E1233 pubmed 出版商
  196. Marquez Vilendrer S, Rai S, Gramling S, Lu L, Reisman D. BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo. Oncoscience. 2016;3:337-350 pubmed 出版商
  197. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, et al. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017;8:14002 pubmed 出版商
  198. Shiina M, Hashimoto Y, Kato T, Yamamura S, Tanaka Y, Majid S, et al. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget. 2017;8:8356-8368 pubmed 出版商
  199. Ramos P, Guerra A, Guerreiro O, Santos S, Oliveira H, Freire C, et al. Antiproliferative Effects of Cynara cardunculus L. var. altilis (DC) Lipophilic Extracts. Int J Mol Sci. 2016;18: pubmed 出版商
  200. Jin X, Wu N, Dai J, Li Q, Xiao X. TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4-phenylbutyrate treatment. Cancer Med. 2017;6:424-438 pubmed 出版商
  201. Song X, Narzt M, Nagelreiter I, Hohensinner P, Terlecki Zaniewicz L, Tschachler E, et al. Autophagy deficient keratinocytes display increased DNA damage, senescence and aberrant lipid composition after oxidative stress in vitro and in vivo. Redox Biol. 2017;11:219-230 pubmed 出版商
  202. Mytych J, Wos I, Solek P, Koziorowski M. Protective role of klotho protein on epithelial cells upon co-culture with activated or senescent monocytes. Exp Cell Res. 2017;350:358-367 pubmed 出版商
  203. Sun J, Liu X, Gao H, Zhang L, Ji Q, Wang Z, et al. Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis. Oncotarget. 2017;8:11489-11506 pubmed 出版商
  204. Choiniere J, Wu J, Wang L. Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol. 2017;91:189-196 pubmed 出版商
  205. Marmisolle I, Martínez J, Liu J, Mastrogiovanni M, Fergusson M, Rovira I, et al. Reciprocal regulation of acetyl-CoA carboxylase 1 and senescence in human fibroblasts involves oxidant mediated p38 MAPK activation. Arch Biochem Biophys. 2017;613:12-22 pubmed 出版商
  206. Yu G, Dou Z, Jia Z. 5?bromo?3?(3?hydroxyprop?1?ynyl)?2H?pyran?2?one induces apoptosis in T24 human bladder cancer cells through mitochondria-dependent signaling pathways. Mol Med Rep. 2017;15:153-159 pubmed 出版商
  207. Tsai C, Lin Y, Huang C, Shih C, Tsai Y, Tsao N, et al. Thrombomodulin regulates monocye differentiation via PKC? and ERK1/2 pathway in vitro and in atherosclerotic artery. Sci Rep. 2016;6:38421 pubmed 出版商
  208. Huang Z, Zhou X, He Y, Ke X, Wen Y, Zou F, et al. Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition. Sci Rep. 2016;6:38072 pubmed 出版商
  209. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez Aguayo C, Fuentes Mattei E, et al. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017;23:2891-2904 pubmed 出版商
  210. Zhu X, Wang K, Zhang K, Zhang T, Yin Y, Xu F. Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis. Int J Mol Sci. 2016;17: pubmed
  211. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, et al. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 2018;106:1-19 pubmed 出版商
  212. Hong Y, Liang H, Uzair Ur Rehman -, Wang Y, Zhang W, Zhou Y, et al. miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 2016;6:37421 pubmed 出版商
  213. Sikander M, Hafeez B, Malik S, Alsayari A, Halaweish F, Yallapu M, et al. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Sci Rep. 2016;6:36594 pubmed 出版商
  214. Kucab J, Hollstein M, Arlt V, Phillips D. Nutlin-3a selects for cells harbouring TP53 mutations. Int J Cancer. 2017;140:877-887 pubmed 出版商
  215. Benkafadar N, Menardo J, Bourien J, Nouvian R, François F, Decaudin D, et al. Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med. 2017;9:7-26 pubmed 出版商
  216. Cholewa B, Ndiaye M, Huang W, Liu X, Ahmad N. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cancer Lett. 2017;385:179-187 pubmed 出版商
  217. Schlierf A, Altmann E, Quancard J, Jefferson A, Assenberg R, Renatus M, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016;7:13166 pubmed 出版商
  218. Andriani G, Almeida V, Faggioli F, Mauro M, Tsai W, Santambrogio L, et al. Whole Chromosome Instability induces senescence and promotes SASP. Sci Rep. 2016;6:35218 pubmed 出版商
  219. Hrgovic I, Doll M, Kleemann J, Wang X, Zoeller N, Pinter A, et al. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer. 2016;16:763 pubmed
  220. Zhao Y, Fan D, Ru B, Cheng K, Hu S, Zhang J, et al. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells. Eur J Cancer. 2016;68:38-50 pubmed 出版商
  221. Zhang Y, Zhang Y, Zhong C, Xiao F. Cr(VI) induces premature senescence through ROS-mediated p53 pathway in L-02 hepatocytes. Sci Rep. 2016;6:34578 pubmed 出版商
  222. Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A, et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun. 2016;7:12852 pubmed 出版商
  223. Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, et al. High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Res. 2016;76:6950-6963 pubmed
  224. Sikora M, Jacobsen B, Levine K, Chen J, Davidson N, Lee A, et al. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016;18:92 pubmed 出版商
  225. Nip H, Dar A, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016;7:68371-68384 pubmed 出版商
  226. Chen P, Qin L, Li G, Tellides G, Simons M. Fibroblast growth factor (FGF) signaling regulates transforming growth factor beta (TGF?)-dependent smooth muscle cell phenotype modulation. Sci Rep. 2016;6:33407 pubmed 出版商
  227. Bellotti C, Capanni C, Lattanzi G, Donati D, Lucarelli E, Duchi S. Detection of mesenchymal stem cells senescence by prelamin A accumulation at the nuclear level. Springerplus. 2016;5:1427 pubmed 出版商
  228. Queisser A, Hagedorn S, Wang H, Schaefer T, Konantz M, Alavi S, et al. Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene. 2017;36:1573-1584 pubmed 出版商
  229. Liu T, Xiong J, Yi S, Zhang H, Zhou S, Gu L, et al. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene. 2017;36:1678-1686 pubmed 出版商
  230. Suman S, Kumar S, N GOUEMO P, Datta K. Increased DNA double-strand break was associated with downregulation of repair and upregulation of apoptotic factors in rat hippocampus after alcohol exposure. Alcohol. 2016;54:45-50 pubmed 出版商
  231. Cunningham C, Li S, Vizeacoumar F, Bhanumathy K, Lee J, Parameswaran S, et al. Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget. 2016;7:61544-61561 pubmed 出版商
  232. Bauer M, Joerger A, Fersht A. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016;113:E5271-80 pubmed 出版商
  233. Nagano T, Nakano M, Nakashima A, Onishi K, Yamao S, Enari M, et al. Identification of cellular senescence-specific genes by comparative transcriptomics. Sci Rep. 2016;6:31758 pubmed 出版商
  234. Hoare M, Ito Y, Kang T, Weekes M, Matheson N, Patten D, et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat Cell Biol. 2016;18:979-92 pubmed 出版商
  235. Kang M, Park K, Yang J, Lee C, Oh S, Yun J, et al. miR-6734 Up-Regulates p21 Gene Expression and Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. PLoS ONE. 2016;11:e0160961 pubmed 出版商
  236. Mihailidou C, Panagiotou C, Kiaris H, Kassi E, Moutsatsou P. Crosstalk between C/EBP homologous protein (CHOP) and glucocorticoid receptor in lung cancer. Mol Cell Endocrinol. 2016;436:211-23 pubmed 出版商
  237. Marquez Vilendrer S, Thompson K, Lu L, Reisman D. Mechanism of BRG1 silencing in primary cancers. Oncotarget. 2016;7:56153-56169 pubmed 出版商
  238. Hauck L, Grothe D, Billia F. p21(CIP1/WAF1)-dependent inhibition of cardiac hypertrophy in response to Angiotensin II involves Akt/Myc and pRb signaling. Peptides. 2016;83:38-48 pubmed 出版商
  239. Rada M, Vasileva E, Lezina L, Marouco D, Antonov A, Macip S, et al. Human EHMT2/G9a activates p53 through methylation-independent mechanism. Oncogene. 2017;36:922-932 pubmed 出版商
  240. Grinshtein N, Rioseco C, Marcellus R, UEHLING D, Aman A, Lun X, et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget. 2016;7:59360-59376 pubmed 出版商
  241. Lu H, Yang X, Tian X, Tang S, Li L, Zhao S, et al. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells. Oncotarget. 2016;7:56508-56525 pubmed 出版商
  242. Meitinger F, Anzola J, Kaulich M, Richardson A, Stender J, Benner C, et al. 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration. J Cell Biol. 2016;214:155-66 pubmed 出版商
  243. Hampp S, Kiessling T, Buechle K, Mansilla S, Thomale J, Rall M, et al. DNA damage tolerance pathway involving DNA polymerase ? and the tumor suppressor p53 regulates DNA replication fork progression. Proc Natl Acad Sci U S A. 2016;113:E4311-9 pubmed 出版商
  244. Grassi M, Palma C, Thomé C, Lanfredi G, Poersch A, Faça V. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. J Proteomics. 2017;151:2-11 pubmed 出版商
  245. Janer A, Prudent J, Paupe V, Fahiminiya S, Majewski J, Sgarioto N, et al. SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med. 2016;8:1019-38 pubmed 出版商
  246. Lefort K, Ostano P, Mello Grand M, Calpini V, Scatolini M, Farsetti A, et al. Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer. Oncotarget. 2016;7:48011-48026 pubmed 出版商
  247. Janjanam J, Rao G. Novel role of cortactin in G protein-coupled receptor agonist-induced nuclear export and degradation of p21Cip1. Sci Rep. 2016;6:28687 pubmed 出版商
  248. Dutta A, Le Magnen C, Mitrofanova A, Ouyang X, Califano A, Abate Shen C. Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation. Science. 2016;352:1576-80 pubmed 出版商
  249. Hong A, Tseng Y, Cowley G, Jonas O, Cheah J, Kynnap B, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016;7:11987 pubmed 出版商
  250. Esmaeili M, Pungsrinont T, Schaefer A, Baniahmad A. A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling. J Mol Med (Berl). 2016;94:1167-1179 pubmed
  251. Zeng L, Yang X, Wen Y, Mail S, Wang M, Zhang M, et al. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY). 2016;8:1236-49 pubmed 出版商
  252. Jeong A, Han S, Lee S, Su Park J, Lu Y, Yu S, et al. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. Sci Rep. 2016;6:27391 pubmed 出版商
  253. Nicolas E, Parisot P, Pinto Monteiro C, de Walque R, De Vleeschouwer C, Lafontaine D. Involvement of human ribosomal proteins in nucleolar structure and p53-dependent nucleolar stress. Nat Commun. 2016;7:11390 pubmed 出版商
  254. Penterling C, Drexler G, Böhland C, Stamp R, Wilke C, Braselmann H, et al. Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair. PLoS ONE. 2016;11:e0156599 pubmed 出版商
  255. Hendrayani S, Al Harbi B, Al Ansari M, Silva G, Aboussekhra A. The inflammatory/cancer-related IL-6/STAT3/NF-?B positive feedback loop includes AUF1 and maintains the active state of breast myofibroblasts. Oncotarget. 2016;7:41974-41985 pubmed 出版商
  256. Chesnokova V, Zonis S, Zhou C, Recouvreux M, Ben Shlomo A, Araki T, et al. Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci U S A. 2016;113:E3250-9 pubmed 出版商
  257. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, et al. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 2016;7:11363 pubmed 出版商
  258. Chen P, Qin L, Li G, Tellides G, Simons M. Smooth muscle FGF/TGFβ cross talk regulates atherosclerosis progression. EMBO Mol Med. 2016;8:712-28 pubmed 出版商
  259. Chen R, Liu H, Cheng Q, Jiang B, Peng R, Zou Q, et al. MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide. Biol Open. 2016;5:669-77 pubmed 出版商
  260. Yang Y, Lu Y, Wang L, Mizokami A, Keller E, Zhang J, et al. Skp2 is associated with paclitaxel resistance in prostate cancer cells. Oncol Rep. 2016;36:559-66 pubmed 出版商
  261. Ho T, Guilbaud G, Blow J, Sale J, Watson C. The KRAB Zinc Finger Protein Roma/Zfp157 Is a Critical Regulator of Cell-Cycle Progression and Genomic Stability. Cell Rep. 2016;15:724-734 pubmed 出版商
  262. O Santos A, Parrini M, Camonis J. RalGPS2 Is Essential for Survival and Cell Cycle Progression of Lung Cancer Cells Independently of Its Established Substrates Ral GTPases. PLoS ONE. 2016;11:e0154840 pubmed 出版商
  263. Avila A, Illing A, Becker F, Maerz L, Morita Y, Philipp M, et al. Xpg limits the expansion of haematopoietic stem and progenitor cells after ionising radiation. Nucleic Acids Res. 2016;44:6252-61 pubmed 出版商
  264. Chen Y, Pan K, Wang P, Cao Z, Wang W, Wang S, et al. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis. J Biol Chem. 2016;291:12688-705 pubmed 出版商
  265. Zhuang L, Yang Y, Ma X, Han B, Wang Z, Zhao Q, et al. MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis. 2016;7:e2203 pubmed 出版商
  266. Chaudhary S, Madhukrishna B, Adhya A, Keshari S, Mishra S. Overexpression of caspase 7 is ER? dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip). Oncogenesis. 2016;5:e219 pubmed 出版商
  267. He D, Xiang J, Li B, Liu H. The dynamic behavior of Ect2 in response to DNA damage. Sci Rep. 2016;6:24504 pubmed 出版商
  268. Dey A, Mustafi S, Saha S, Kumar Dhar Dwivedi S, Mukherjee P, Bhattacharya R. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016;12:659-70 pubmed 出版商
  269. Seidel P, Remus M, Delacher M, Grigaravicius P, Reuss D, Frappart L, et al. Epidermal Nbn deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. Oncotarget. 2016;7:23006-18 pubmed 出版商
  270. Yosef R, Pilpel N, Tokarsky Amiel R, Biran A, Ovadya Y, Cohen S, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7:11190 pubmed 出版商
  271. Kaur A, Webster M, Marchbank K, Behera R, Ndoye A, Kugel C, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532:250-4 pubmed 出版商
  272. Yan B, Zhang Z, Jin D, Cai C, Jia C, Liu W, et al. mTORC1 regulates PTHrP to coordinate chondrocyte growth, proliferation and differentiation. Nat Commun. 2016;7:11151 pubmed 出版商
  273. Garcia C, Videla Richardson G, Dimopoulos N, Fernandez Espinosa D, Miriuka S, Sevlever G, et al. Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199. PLoS ONE. 2016;11:e0152607 pubmed 出版商
  274. Jung Y, Decker A, Wang J, Lee E, Kana L, Yumoto K, et al. Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget. 2016;7:25698-711 pubmed 出版商
  275. Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, et al. Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci. 2016;107:734-45 pubmed 出版商
  276. Cao C, Wang Z, Huang L, Bai L, Wang Y, Liang Y, et al. Down-regulation of tumor endothelial marker 8 suppresses cell proliferation mediated by ERK1/2 activity. Sci Rep. 2016;6:23419 pubmed 出版商
  277. Lee H, Dai F, Zhuang L, Xiao Z, Kim J, Zhang Y, et al. BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21. Oncotarget. 2016;7:19134-46 pubmed 出版商
  278. Weeks R, Ludgate J, LeMée G, Morison I. TESTIN Induces Rapid Death and Suppresses Proliferation in Childhood B Acute Lymphoblastic Leukaemia Cells. PLoS ONE. 2016;11:e0151341 pubmed 出版商
  279. Guo X, Hollander L, MacPherson D, Wang L, Velazquez H, Chang J, et al. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Sci Rep. 2016;6:22996 pubmed 出版商
  280. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed 出版商
  281. Atiq R, Hertz R, Eldad S, Smeir E, Bar Tana J. Suppression of B-Raf(V600E) cancers by MAPK hyper-activation. Oncotarget. 2016;7:18694-704 pubmed 出版商
  282. Yeo S, Itahana Y, Guo A, Han R, Iwamoto K, Nguyen H, et al. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation. elife. 2016;5:e07101 pubmed 出版商
  283. Shao Z, Zhang R, Khodadadi Jamayran A, Chen B, Crowley M, Festok M, et al. The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis. Nat Commun. 2016;7:10869 pubmed 出版商
  284. Barroso González J, Auclair S, Luan S, Thomas L, Atkins K, Aslan J, et al. PACS-2 mediates the ATM and NF-κB-dependent induction of anti-apoptotic Bcl-xL in response to DNA damage. Cell Death Differ. 2016;23:1448-57 pubmed 出版商
  285. Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016;15:628-39 pubmed 出版商
  286. McNaughton M, Pitman M, Pitson S, Pyne N, Pyne S. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget. 2016;7:16663-75 pubmed 出版商
  287. Nakayama R, Zhang Y, Czaplinski J, Anatone A, Sicinska E, Fletcher J, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7:16581-92 pubmed 出版商
  288. Randles L, Anchoori R, Roden R, Walters K. The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem. 2016;291:8773-83 pubmed 出版商
  289. Kan H, Huang Y, Li X, Liu D, Chen J, Shu M. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1. Oncotarget. 2016;7:14336-49 pubmed 出版商
  290. Kang L, Yao C, Khodadadi Jamayran A, Xu W, Zhang R, Banerjee N, et al. The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells. Stem Cells Dev. 2016;25:556-68 pubmed 出版商
  291. Liu X, Tan Y, Zhang C, Zhang Y, Zhang L, Ren P, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17:349-66 pubmed 出版商
  292. Xie X, Lozano G, Siddik Z. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016;35:4798-806 pubmed 出版商
  293. Gerashchenko B, Salmina K, Eglitis J, Huna A, Grjunberga V, Erenpreisa J. Disentangling the aneuploidy and senescence paradoxes: a study of triploid breast cancers non-responsive to neoadjuvant therapy. Histochem Cell Biol. 2016;145:497-508 pubmed 出版商
  294. Niopek D, Wehler P, Roensch J, Eils R, Di Ventura B. Optogenetic control of nuclear protein export. Nat Commun. 2016;7:10624 pubmed 出版商
  295. Le Pen J, Maillet L, Sarosiek K, Vuillier C, Gautier F, Montessuit S, et al. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL. Cell Death Dis. 2016;7:e2083 pubmed 出版商
  296. Llanos S, García Pedrero J, Morgado Palacin L, Rodrigo J, Serrano M. Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers. Nat Commun. 2016;7:10438 pubmed 出版商
  297. Le Trilling V, Megger D, Katschinski B, Landsberg C, Rückborn M, Tao S, et al. Broad and potent antiviral activity of the NAE inhibitor MLN4924. Sci Rep. 2016;6:19977 pubmed 出版商
  298. Podmirseg S, Jäkel H, Ranches G, Kullmann M, Sohm B, Villunger A, et al. Caspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion. Oncogene. 2016;35:4580-90 pubmed 出版商
  299. Nassour J, Martien S, Martin N, Deruy E, Tomellini E, Malaquin N, et al. Defective DNA single-strand break repair is responsible for senescence and neoplastic escape of epithelial cells. Nat Commun. 2016;7:10399 pubmed 出版商
  300. Qiu L, Wu J, Pan C, Tan X, Lin J, Liu R, et al. Downregulation of CDC27 inhibits the proliferation of colorectal cancer cells via the accumulation of p21Cip1/Waf1. Cell Death Dis. 2016;7:e2074 pubmed 出版商
  301. Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed 出版商
  302. Zhu N, Wang H, Wang B, Wei J, Shan W, Feng J, et al. A Member of the Nuclear Receptor Superfamily, Designated as NR2F2, Supports the Self-Renewal Capacity and Pluripotency of Human Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells Int. 2016;2016:5687589 pubmed 出版商
  303. Mo X, Cao Q, Liang H, Liu J, Li H, Liu F. MicroRNA-610 suppresses the proliferation of human glioblastoma cells by repressing CCND2 and AKT3. Mol Med Rep. 2016;13:1961-6 pubmed 出版商
  304. Cousin F, Jouan Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne Muller G, et al. The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget. 2016;7:7161-78 pubmed 出版商
  305. Wu B, Chen H, Cai C, Fang J, Wu C, Huang L, et al. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686. Oncotarget. 2016;7:6847-63 pubmed 出版商
  306. Guo Z, Kong Q, Liu C, Zhang S, Zou L, Yan F, et al. DCAF1 controls T-cell function via p53-dependent and -independent mechanisms. Nat Commun. 2016;7:10307 pubmed 出版商
  307. Berges C, Chatterjee M, Topp M, Einsele H. Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells. Immunol Res. 2016;64:687-98 pubmed 出版商
  308. Kucab J, Zwart E, van Steeg H, Luijten M, Schmeiser H, Phillips D, et al. TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts. DNA Repair (Amst). 2016;39:21-33 pubmed 出版商
  309. Vartanian S, Ma T, Lee J, Haverty P, Kirkpatrick D, Yu K, et al. Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis. Mol Cell Proteomics. 2016;15:1220-31 pubmed 出版商
  310. García V, Lara Chica M, Cantarero I, Sterner O, Calzado M, Muñoz E. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. Oncotarget. 2016;7:4490-506 pubmed 出版商
  311. Ding X, Jiang W, Zhou P, Liu L, Wan X, Yuan X, et al. Mixed Lineage Leukemia 5 (MLL5) Protein Stability Is Cooperatively Regulated by O-GlcNac Transferase (OGT) and Ubiquitin Specific Protease 7 (USP7). PLoS ONE. 2015;10:e0145023 pubmed 出版商
  312. Guo X, Wang X, Wang Z, Banerjee S, Yang J, Huang L, et al. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat Cell Biol. 2016;18:202-12 pubmed 出版商
  313. Marazita M, Dugour A, Marquioni Ramella M, Figueroa J, Suburo A. Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: Implications for Age-related Macular Degeneration. Redox Biol. 2016;7:78-87 pubmed 出版商
  314. Kondo H, Kim H, Wang L, Okada M, Paul C, Millard R, et al. Blockade of senescence-associated microRNA-195 in aged skeletal muscle cells facilitates reprogramming to produce induced pluripotent stem cells. Aging Cell. 2016;15:56-66 pubmed 出版商
  315. Trzeciecka A, Klossowski S, Bajor M, Zagozdzon R, Gaj P, Muchowicz A, et al. Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. Oncotarget. 2016;7:1717-31 pubmed 出版商
  316. Suvorova I, Grigorash B, Chuykin I, Pospelova T, Pospelov V. G1 checkpoint is compromised in mouse ESCs due to functional uncoupling of p53-p21Waf1 signaling. Cell Cycle. 2016;15:52-63 pubmed 出版商
  317. Mehraein Ghomi F, Church D, Schreiber C, Weichmann A, Basu H, Wilding G. Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81). Genes Cancer. 2015;6:428-44 pubmed
  318. Huang Y, Chen N, Miao D. Biological effects of pyrroloquinoline quinone on liver damage in Bmi-1 knockout mice. Exp Ther Med. 2015;10:451-458 pubmed
  319. Wang G, Yu Y, Sun C, Liu T, Liang T, Zhan L, et al. STAT3 selectively interacts with Smad3 to antagonize TGF-β signalling. Oncogene. 2016;35:4388-98 pubmed 出版商
  320. Martín Pardillos A, Sorribas V. Effects of donor age and proliferative aging on the phenotype stability of rat aortic smooth muscle cells. Physiol Rep. 2015;3: pubmed 出版商
  321. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo S, Low D, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126:68-84 pubmed 出版商
  322. Manojlović Gacić E, Skender Gazibara M, Popovic V, Soldatovic I, Boricic N, Raičević S, et al. Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study. Endocr Pathol. 2016;27:1-11 pubmed 出版商
  323. Zhu J, Wang S, Zhang W, Qiu J, Shan Y, Yang D, et al. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network. Oncotarget. 2015;6:43819-30 pubmed 出版商
  324. Kraut B, Maier H, Kókai E, Fiedler K, Boettger T, Illing A, et al. Cardiac-Specific Activation of IKK2 Leads to Defects in Heart Development and Embryonic Lethality. PLoS ONE. 2015;10:e0141591 pubmed 出版商
  325. Rohnalter V, Roth K, Finkernagel F, Adhikary T, Obert J, Dorzweiler K, et al. A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget. 2015;6:40005-25 pubmed 出版商
  326. Bauer J, Ozden O, Akagi N, Carroll T, Principe D, Staudacher J, et al. Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer. Mol Cancer. 2015;14:182 pubmed 出版商
  327. Tonsing Carter E, Bailey B, Saadatzadeh M, Ding J, Wang H, Sinn A, et al. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther. 2015;14:2850-63 pubmed 出版商
  328. Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, et al. CGK733-induced LC3 II formation is positively associated with the expression of cyclin-dependent kinase inhibitor p21Waf1/Cip1 through modulation of the AMPK and PERK/CHOP signaling pathways. Oncotarget. 2015;6:39692-701 pubmed 出版商
  329. Vétillard A, Jonchère B, Moreau M, Toutain B, Henry C, Fontanel S, et al. Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. Oncotarget. 2015;6:43342-62 pubmed 出版商
  330. Xiong Y, Su H, Lv P, Ma Y, Wang S, Miao H, et al. A newly identified berberine derivative induces cancer cell senescence by stabilizing endogenous G-quadruplexes and sparking a DNA damage response at the telomere region. Oncotarget. 2015;6:35625-35 pubmed 出版商
  331. Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R. PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget. 2015;6:30957-67 pubmed 出版商
  332. Felli N, Errico M, Pedini F, Petrini M, Puglisi R, Bellenghi M, et al. AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression. Oncogene. 2016;35:3016-26 pubmed 出版商
  333. Hu D, Gur M, Zhou Z, Gamper A, Hung M, Fujita N, et al. Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. Nat Commun. 2015;6:8419 pubmed 出版商
  334. Daou S, Hammond Martel I, Mashtalir N, Barbour H, Gagnon J, Iannantuono N, et al. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer. J Biol Chem. 2015;290:28643-63 pubmed 出版商
  335. Xing M, Wang X, Palmai Pallag T, Shen H, Helleday T, Hickson I, et al. Acute MUS81 depletion leads to replication fork slowing and a constitutive DNA damage response. Oncotarget. 2015;6:37638-46 pubmed 出版商
  336. Anderson K, Russell A, Foletta V. NDRG2 promotes myoblast proliferation and caspase 3/7 activities during differentiation, and attenuates hydrogen peroxide - But not palmitate-induced toxicity. FEBS Open Bio. 2015;5:668-81 pubmed 出版商
  337. Lee N, Kwon J, Kim Y, Kim S, Park S, Xu W, et al. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition. Oncotarget. 2015;6:30130-48 pubmed 出版商
  338. Kim Y, Chen C, Bolton E. Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells. PLoS ONE. 2015;10:e0138286 pubmed 出版商
  339. Pacini L, Savini C, Ghittoni R, Saidj D, Lamartine J, Hasan U, et al. Downregulation of Toll-Like Receptor 9 Expression by Beta Human Papillomavirus 38 and Implications for Cell Cycle Control. J Virol. 2015;89:11396-405 pubmed 出版商
  340. Moussa R, Kovacevic Z, Richardson D. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget. 2015;6:29694-711 pubmed 出版商
  341. Wang J, Hua W, Huang S, Fan K, Takeshima L, Mao Y, et al. RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb. Oncotarget. 2015;6:30165-77 pubmed 出版商
  342. Mansara P, Deshpande R, Vaidya M, Kaul Ghanekar R. Differential Ratios of Omega Fatty Acids (AA/EPA+DHA) Modulate Growth, Lipid Peroxidation and Expression of Tumor Regulatory MARBPs in Breast Cancer Cell Lines MCF7 and MDA-MB-231. PLoS ONE. 2015;10:e0136542 pubmed 出版商
  343. Chiang K, Chen H, Hsu S, Pang J, Wang S, Hsu J, et al. PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. Drug Des Devel Ther. 2015;9:4631-8 pubmed 出版商
  344. Cañeque T, Gomes F, Mai T, Maestri G, Malacria M, Rodriguez R. Synthesis of marmycin A and investigation into its cellular activity. Nat Chem. 2015;7:744-51 pubmed 出版商
  345. Zhuo W, Ge W, Meng G, Jia S, Zhou X, Liu J. MicroRNA‑20a promotes the proliferation and cell cycle of human osteosarcoma cells by suppressing early growth response 2 expression. Mol Med Rep. 2015;12:4989-94 pubmed 出版商
  346. Marzagalli M, Casati L, Moretti R, Montagnani Marelli M, Limonta P. Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS ONE. 2015;10:e0134396 pubmed 出版商
  347. Zhang X, Wang X, Wu T, Li B, Liu T, Wang R, et al. Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation. Sci Rep. 2015;5:12579 pubmed 出版商
  348. Xie W, Zhang L, Jiao H, Guan L, Zha J, Li X, et al. Chaperone-mediated autophagy prevents apoptosis by degrading BBC3/PUMA. Autophagy. 2015;11:1623-35 pubmed 出版商
  349. Succoio M, Comegna M, D Ambrosio C, Scaloni A, Cimino F, Faraonio R. Proteomic analysis reveals novel common genes modulated in both replicative and stress-induced senescence. J Proteomics. 2015;128:18-29 pubmed 出版商
  350. Navarro F, Lieberman J. miR-34 and p53: New Insights into a Complex Functional Relationship. PLoS ONE. 2015;10:e0132767 pubmed 出版商
  351. Ohashi A, Ohori M, Iwai K, Nakayama Y, Nambu T, Morishita D, et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun. 2015;6:7668 pubmed 出版商
  352. Dong L, Yu D, Wu N, Wang H, Niu J, Wang Y, et al. Echinacoside Induces Apoptosis in Human SW480 Colorectal Cancer Cells by Induction of Oxidative DNA Damages. Int J Mol Sci. 2015;16:14655-68 pubmed 出版商
  353. Seo G, Ho M, Bui N, Kim Y, Koh D, Lim Y, et al. Novel naphthochalcone derivative accelerate dermal wound healing through induction of epithelial-mesenchymal transition of keratinocyte. J Biomed Sci. 2015;22:47 pubmed 出版商
  354. Deben C, Wouters A, Op de Beeck K, Van den Bossche J, Jacobs J, Zwaenepoel K, et al. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget. 2015;6:22666-79 pubmed
  355. Huna A, Salmina K, Erenpreisa J, Vazquez Martin A, Krigerts J, Inashkina I, et al. Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide. Cell Cycle. 2015;14:2969-84 pubmed 出版商
  356. Trokovic R, Weltner J, Noisa P, Raivio T, Otonkoski T. Combined negative effect of donor age and time in culture on the reprogramming efficiency into induced pluripotent stem cells. Stem Cell Res. 2015;15:254-62 pubmed 出版商
  357. Galoian K, Qureshi A, D Ippolito G, Schiller P, Molinari M, Johnstone A, et al. Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1. Int J Oncol. 2015;47:465-72 pubmed 出版商
  358. Ge F, Chen W, Qin J, Zhou Z, Liu R, Liu L, et al. Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5). Oncotarget. 2015;6:21369-78 pubmed
  359. Bock F, Tanzer M, Haschka M, Krumschnabel G, Sohm B, Goetsch K, et al. The p53 binding protein PDCD5 is not rate-limiting in DNA damage induced cell death. Sci Rep. 2015;5:11268 pubmed 出版商
  360. Rueda Rincon N, Bloch K, Derua R, Vyas R, Harms A, Hankemeier T, et al. p53 attenuates AKT signaling by modulating membrane phospholipid composition. Oncotarget. 2015;6:21240-54 pubmed
  361. Xie C, Wei D, Zhao L, Marchetto S, Mei L, Borg J, et al. Erbin is a novel substrate of the Sag-βTrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis. J Cell Biol. 2015;209:721-37 pubmed 出版商
  362. Kotipatruni R, Ren X, Thotala D, Jaboin J. NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells. Oncotarget. 2015;6:17594-604 pubmed
  363. Cheedipudi S, Puri D, Saleh A, Gala H, Rumman M, Pillai M, et al. A fine balance: epigenetic control of cellular quiescence by the tumor suppressor PRDM2/RIZ at a bivalent domain in the cyclin a gene. Nucleic Acids Res. 2015;43:6236-56 pubmed 出版商
  364. Velichko A, Petrova N, Razin S, Kantidze O. Mechanism of heat stress-induced cellular senescence elucidates the exclusive vulnerability of early S-phase cells to mild genotoxic stress. Nucleic Acids Res. 2015;43:6309-20 pubmed 出版商
  365. Moiseeva O, Lessard F, Acevedo Aquino M, Vernier M, Tsantrizos Y, Ferbeyre G. Mutant lamin A links prophase to a p53 independent senescence program. Cell Cycle. 2015;14:2408-21 pubmed 出版商
  366. Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton J, et al. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC Cancer. 2015;15:444 pubmed 出版商
  367. Yang K, Kohler R, Landon M, Giedt R, Weissleder R. Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Sci Rep. 2015;5:10129 pubmed 出版商
  368. Scala F, Brighenti E, Govoni M, Imbrogno E, Fornari F, Treré D, et al. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate. Oncogene. 2016;35:977-89 pubmed 出版商
  369. Andries V, Vandepoele K, Staes K, Berx G, Bogaert P, Van Isterdael G, et al. NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest. BMC Cancer. 2015;15:391 pubmed 出版商
  370. Bánfi G, Teleki I, Nyirády P, Keszthelyi A, Romics I, Fintha A, et al. Changes of protein expression in prostate cancer having lost its androgen sensitivity. Int Urol Nephrol. 2015;47:1149-54 pubmed 出版商
  371. Guha G, Lu W, Li S, Liang X, Kulesz Martin M, Mahmud T, et al. Novel Pactamycin Analogs Induce p53 Dependent Cell-Cycle Arrest at S-Phase in Human Head and Neck Squamous Cell Carcinoma (HNSCC) Cells. PLoS ONE. 2015;10:e0125322 pubmed 出版商
  372. Qiu J, Zhang Y, Li Y, Zhao J, Zhang W, Jiang Q, et al. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget. 2015;6:15494-509 pubmed
  373. Pozo K, Hillmann A, Augustyn A, Plattner F, Hai T, Singh T, et al. Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis. Oncotarget. 2015;6:12080-93 pubmed
  374. Ahronian L, Driscoll D, Klimstra D, Lewis B. The p53R172H mutant does not enhance hepatocellular carcinoma development and progression. PLoS ONE. 2015;10:e0123816 pubmed 出版商
  375. Chen P, Wu T, Cheng Y, Chen C, Lee H. NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation. Oncotarget. 2015;6:14274-89 pubmed
  376. Ross J, Huh D, Noble L, Tavazoie S. Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat Cell Biol. 2015;17:651-64 pubmed 出版商
  377. Gillory L, Stewart J, Megison M, Waters A, Beierle E. Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival. J Surg Res. 2015;196:339-49 pubmed 出版商
  378. Rodríguez Sureda V, Vilches Ã, Sánchez O, Audí L, Domínguez C. Intracellular oxidant activity, antioxidant enzyme defense system, and cell senescence in fibroblasts with trisomy 21. Oxid Med Cell Longev. 2015;2015:509241 pubmed 出版商
  379. Saha K, Eckert R. Methylosome Protein 50 and PKC?/p38? Protein Signaling Control Keratinocyte Proliferation via Opposing Effects on p21Cip1 Gene Expression. J Biol Chem. 2015;290:13521-30 pubmed 出版商
  380. Li Y, Li B, Xu B, Han B, Xia H, Chen Q, et al. Expression of p53, p21(CIP1/WAF1) and eIF4E in the adjacent tissues of oral squamous cell carcinoma: establishing the molecular boundary and a cancer progression model. Int J Oral Sci. 2015;7:161-8 pubmed 出版商
  381. Scialpi F, Mellis D, Ditzel M. EDD, a ubiquitin-protein ligase of the N-end rule pathway, associates with spindle assembly checkpoint components and regulates the mitotic response to nocodazole. J Biol Chem. 2015;290:12585-94 pubmed 出版商
  382. Beier J, Jokinen J, Holz G, Whang P, Martin A, Warner N, et al. Novel mechanism of arenavirus-induced liver pathology. PLoS ONE. 2015;10:e0122839 pubmed 出版商
  383. Meena J, Cerutti A, Beichler C, Morita Y, Bruhn C, Kumar M, et al. Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion. EMBO J. 2015;34:1371-84 pubmed 出版商
  384. Markkanen E, Fischer R, Ledentcova M, Kessler B, Dianov G. Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability. Nucleic Acids Res. 2015;43:3667-79 pubmed 出版商
  385. Kirschner K, Samarajiwa S, Cairns J, Menon S, Perez Mancera P, Tomimatsu K, et al. Phenotype specific analyses reveal distinct regulatory mechanism for chronically activated p53. PLoS Genet. 2015;11:e1005053 pubmed 出版商
  386. Xie W, Pariollaud M, Wixted W, Chitnis N, Fornwald J, Truong M, et al. Identification and characterization of PERK activators by phenotypic screening and their effects on NRF2 activation. PLoS ONE. 2015;10:e0119738 pubmed 出版商
  387. Wang Y, Han A, Chen E, Singh R, Chichester C, Moore R, et al. The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol. 2015;46:1924-34 pubmed 出版商
  388. Khoronenkova S, Dianov G. ATM prevents DSB formation by coordinating SSB repair and cell cycle progression. Proc Natl Acad Sci U S A. 2015;112:3997-4002 pubmed 出版商
  389. Wang B, Wu S, Tang S, Lai C, Ou C, Wu M, et al. Benzo[a]pyrene-induced cell cycle progression occurs via ERK-induced Chk1 pathway activation in human lung cancer cells. Mutat Res. 2015;773:1-8 pubmed 出版商
  390. Howlin J, Cirenajwis H, Lettiero B, Staaf J, Lauss M, Saal L, et al. Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours. Peerj. 2015;3:e788 pubmed 出版商
  391. Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt L, Hejhal T, et al. A versatile modular vector system for rapid combinatorial mammalian genetics. J Clin Invest. 2015;125:1603-19 pubmed 出版商
  392. Hallett R, Huang C, Motazedian A, Auf der Mauer S, Pond G, Hassell J, et al. Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy. Oncotarget. 2015;6:7040-52 pubmed
  393. Ungefroren H, Hyder A, Hinz H, Groth S, Lange H, El Sayed K, et al. Pluripotency gene expression and growth control in cultures of peripheral blood monocytes during their conversion into programmable cells of monocytic origin (PCMO): evidence for a regulatory role of autocrine activin and TGF-β. PLoS ONE. 2015;10:e0118097 pubmed 出版商
  394. Susanto J, Colvin E, Pinese M, Chang D, Pajic M, Mawson A, et al. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. Int J Oncol. 2015;46:2223-30 pubmed 出版商
  395. Gergics P, Brinkmeier M, Camper S. Lhx4 deficiency: increased cyclin-dependent kinase inhibitor expression and pituitary hypoplasia. Mol Endocrinol. 2015;29:597-612 pubmed 出版商
  396. Chen Y, Terajima M, Yang Y, Sun L, Ahn Y, Panková D, et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015;125:1147-62 pubmed 出版商
  397. Brazina J, Svadlenka J, Macurek L, Andera L, Hodny Z, Bartek J, et al. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase. Cell Cycle. 2015;14:375-87 pubmed 出版商
  398. Guerrero A, Iglesias C, Raguz S, Floridia E, Gil J, Pombo C, et al. The cerebral cavernous malformation 3 gene is necessary for senescence induction. Aging Cell. 2015;14:274-83 pubmed 出版商
  399. Rao R, Dhele N, Cheemadan S, Ketkar A, Jayandharan G, Palakodeti D, et al. Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci Rep. 2015;5:8229 pubmed 出版商
  400. Suo H, Song J, Zhou Y, Liu Z, Yi R, Zhu K, et al. Induction of apoptosis in HCT-116 colon cancer cells by polysaccharide of Larimichthys crocea swim bladder. Oncol Lett. 2015;9:972-978 pubmed
  401. Iglesias Gato D, Chuan Y, Jiang N, Svensson C, Bao J, Paul I, et al. OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer. 2015;14:8 pubmed 出版商
  402. Cai K, Wang Y, Smith E, Smedberg J, Yang D, Yang W, et al. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice. Neoplasia. 2015;17:89-100 pubmed 出版商
  403. Raouf S, Weston C, Yucel N. Registered report: senescence surveillance of pre-malignant hepatocytes limits liver cancer development. elife. 2015;4: pubmed 出版商
  404. Tao Y, Xu L, Lu J, Hu S, Fang F, Cao L, et al. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia. J Exp Clin Cancer Res. 2015;34:4 pubmed 出版商
  405. Vosper J, Masuccio A, Kullmann M, Ploner C, Geley S, Hengst L. Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation. Oncotarget. 2015;6:2889-902 pubmed
  406. Feng T, Dzieran J, Gu X, Marhenke S, Vogel A, Machida K, et al. Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. Clin Sci (Lond). 2015;128:761-74 pubmed 出版商
  407. Silva V, Plooster M, Leung J, Cassimeris L. A delay prior to mitotic entry triggers caspase 8-dependent cell death in p53-deficient Hela and HCT-116 cells. Cell Cycle. 2015;14:1070-81 pubmed 出版商
  408. Wang L, Liu R, Ye P, Wong C, Chen G, Zhou P, et al. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nat Commun. 2015;6:5909 pubmed 出版商
  409. Chong K, Hsu C, Hung T, Hu H, Huang T, Wang T, et al. Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells. Cancer Biol Ther. 2015;16:149-59 pubmed 出版商
  410. Azimzadeh O, Sievert W, Sarioglu H, Merl Pham J, Yentrapalli R, Bakshi M, et al. Integrative proteomics and targeted transcriptomics analyses in cardiac endothelial cells unravel mechanisms of long-term radiation-induced vascular dysfunction. J Proteome Res. 2015;14:1203-19 pubmed 出版商
  411. Jonchère B, Vétillard A, Toutain B, Lam D, Bernard A, Henry C, et al. Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. Oncotarget. 2015;6:409-26 pubmed
  412. Suzuki D, Sahu R, Leu N, Senoo M. The carboxy-terminus of p63 links cell cycle control and the proliferative potential of epidermal progenitor cells. Development. 2015;142:282-90 pubmed 出版商
  413. Yang Z, Broz D, Noderer W, Ferreira J, Overton K, Spencer S, et al. p53 suppresses muscle differentiation at the myogenin step in response to genotoxic stress. Cell Death Differ. 2015;22:560-73 pubmed 出版商
  414. Myklebust L, Van Damme P, Støve S, Dörfel M, Abboud A, Kalvik T, et al. Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects. Hum Mol Genet. 2015;24:1956-76 pubmed 出版商
  415. Wei Z, Guo H, Liu Z, Zhang X, Liu Q, Qian Y, et al. CUL4B impedes stress-induced cellular senescence by dampening a p53-reactive oxygen species positive feedback loop. Free Radic Biol Med. 2015;79:1-13 pubmed 出版商
  416. Mohan M, Kumar V, Lackner A, Alvarez X. Dysregulated miR-34a-SIRT1-acetyl p65 axis is a potential mediator of immune activation in the colon during chronic simian immunodeficiency virus infection of rhesus macaques. J Immunol. 2015;194:291-306 pubmed 出版商
  417. Kim H, Jung G. Reactive oxygen species increase HEPN1 expression via activation of the XBP1 transcription factor. FEBS Lett. 2014;588:4413-21 pubmed 出版商
  418. Kim T, Kim H, Kang Y, Yoon S, Lee J, Choi W, et al. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts. Biochim Biophys Acta. 2015;1850:401-10 pubmed 出版商
  419. Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, et al. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget. 2014;5:10607-20 pubmed
  420. Peterson E, Menon V, Gatti L, Kipping R, Dewasinghe D, Perego P, et al. Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction. Mol Pharm. 2015;12:287-97 pubmed 出版商
  421. Bongers K, Fox D, Kunkel S, Stebounova L, Murry D, Pufall M, et al. Spermine oxidase maintains basal skeletal muscle gene expression and fiber size and is strongly repressed by conditions that cause skeletal muscle atrophy. Am J Physiol Endocrinol Metab. 2015;308:E144-58 pubmed 出版商
  422. Wohak L, Krais A, Kucab J, Stertmann J, Øvrebø S, Seidel A, et al. Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch Toxicol. 2016;90:291-304 pubmed 出版商
  423. Chen J, Shin J, Zhao R, Phan L, Wang H, Xue Y, et al. CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun. 2014;5:5384 pubmed 出版商
  424. Liu X, Yang W, Zheng P. Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas. Oncotarget. 2014;5:10870-85 pubmed
  425. Gao L, Fang Y, Zhang T, Ge B, Xu B, Huang J, et al. GSTP1 arrests bladder cancer T24 cells in G0/G1 phase and up-regulates p21 expression. Int J Clin Exp Med. 2014;7:2984-91 pubmed
  426. Xu J, Huang Z, Lin L, Fu M, Song Y, Shen Y, et al. miRNA-130b is required for the ERK/FOXM1 pathway activation-mediated protective effects of isosorbide dinitrate against mesenchymal stem cell senescence induced by high glucose. Int J Mol Med. 2015;35:59-71 pubmed 出版商
  427. Xu H, Zhou Y, Coughlan K, Ding Y, Wang S, Wu Y, et al. AMPKα1 deficiency promotes cellular proliferation and DNA damage via p21 reduction in mouse embryonic fibroblasts. Biochim Biophys Acta. 2015;1853:65-73 pubmed 出版商
  428. Dettmering T, Zahnreich S, Colindres Rojas M, Durante M, Taucher Scholz G, Fournier C. Increased effectiveness of carbon ions in the production of reactive oxygen species in normal human fibroblasts. J Radiat Res. 2015;56:67-76 pubmed 出版商
  429. Wang T, Guo S, Liu Z, Wu L, Li M, Yang J, et al. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget. 2014;5:10293-306 pubmed
  430. Brun C, Périé L, Baraige F, Vernus B, Bonnieu A, Blanquet V. Absence of hyperplasia in Gasp-1 overexpressing mice is dependent on myostatin up-regulation. Cell Physiol Biochem. 2014;34:1241-59 pubmed 出版商
  431. Wang Y, Kuramitsu Y, Tokuda K, Baron B, Kitagawa T, Akada J, et al. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS ONE. 2014;9:e109076 pubmed 出版商
  432. Overton K, Spencer S, Noderer W, Meyer T, Wang C. Basal p21 controls population heterogeneity in cycling and quiescent cell cycle states. Proc Natl Acad Sci U S A. 2014;111:E4386-93 pubmed 出版商
  433. Cuevas Ramos D, Carmichael J, Cooper O, Bonert V, Gertych A, Mamelak A, et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100:122-31 pubmed 出版商
  434. Ono Y, Terai Y, Tanabe A, Hayashi A, Hayashi M, Yamashita Y, et al. Decorin induced by progesterone plays a crucial role in suppressing endometriosis. J Endocrinol. 2014;223:203-16 pubmed 出版商
  435. Wei H, Nickoloff J, Chen W, Liu H, Lo W, Chang Y, et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget. 2014;5:9514-29 pubmed
  436. Harashima N, Minami T, Uemura H, Harada M. Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system. Mol Cancer. 2014;13:217 pubmed 出版商
  437. Shi Z, Shi F, Wang Y, Sheftel A, Nie G, Zhao Y, et al. Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell proliferation. Cell Mol Life Sci. 2015;72:983-97 pubmed 出版商
  438. Patwardhan G, Hosain S, Liu D, Khiste S, Zhao Y, Bielawski J, et al. Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells. Biochim Biophys Acta. 2014;1841:1571-80 pubmed 出版商
  439. Yang C, Chung A, Ku C, Brill L, Williams R, Wolf D. Systems analysis of the prostate tumor suppressor NKX3.1 supports roles in DNA repair and luminal cell differentiation. F1000Res. 2014;3:115 pubmed 出版商
  440. Qiu M, Liu L, Chen L, Tan G, Liang Z, Wang K, et al. microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. Biochem Biophys Res Commun. 2014;452:163-9 pubmed 出版商
  441. Van Brocklyn J, Wojton J, Meisen W, Kellough D, Ecsedy J, Kaur B, et al. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res. 2014;74:5364-70 pubmed 出版商
  442. Jacob A, Singh R, Comiskey D, Rouhier M, Mohammad F, Bebee T, et al. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. PLoS ONE. 2014;9:e104444 pubmed 出版商
  443. Vassilopoulos A, Tominaga Y, Kim H, Lahusen T, Li B, Yu H, et al. WEE1 murine deficiency induces hyper-activation of APC/C and results in genomic instability and carcinogenesis. Oncogene. 2015;34:3023-35 pubmed 出版商
  444. Zhang X, Ma W, Cui J, Yao H, Zhou H, Ge Y, et al. Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia. Oncogene. 2015;34:3000-10 pubmed 出版商
  445. Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh A, et al. p53? is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci U S A. 2014;111:E3287-96 pubmed 出版商
  446. Hamilton G, Abraham A, Morton J, Sampson O, Pefani D, Khoronenkova S, et al. AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget. 2014;5:6142-67 pubmed
  447. Mungamuri S, Wang S, Manfredi J, Gu W, Aaronson S. Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters. Oncogene. 2015;34:2461-70 pubmed 出版商
  448. Patel A, Burton D, Halvorsen K, Balkan W, Reiner T, Perez Stable C, et al. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. Oncogene. 2015;34:2586-96 pubmed 出版商
  449. Brohl A, Solomon D, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10:e1004475 pubmed 出版商
  450. Yang H, Hwangbo K, Zheng M, Cho J, Son J, Kim H, et al. Inhibitory effects of (-)-loliolide on cellular senescence in human dermal fibroblasts. Arch Pharm Res. 2015;38:876-84 pubmed 出版商
  451. Yamauchi T, Nishiyama M, Moroishi T, Yumimoto K, Nakayama K. MDM2 mediates nonproteolytic polyubiquitylation of the DEAD-Box RNA helicase DDX24. Mol Cell Biol. 2014;34:3321-40 pubmed 出版商
  452. Lau H, Ramanujulu P, Guo D, Yang T, Wirawan M, Casey P, et al. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. Cancer Biol Ther. 2014;15:1280-91 pubmed 出版商
  453. Tabor V, Bocci M, Alikhani N, Kuiper R, Larsson L. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence. Cancer Res. 2014;74:4222-9 pubmed 出版商
  454. Otani K, Dong Y, Li X, Lu J, Zhang N, Xu L, et al. Odd-skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer. J Pathol. 2014;234:302-15 pubmed 出版商
  455. Kaneko Y, Ota A, Nakashima A, Nagasaki H, Kodani Y, Mori K, et al. Lipopolysaccharide treatment arrests the cell cycle of BV-2 microglial cells in G? phase and protects them from UV light-induced apoptosis. J Neural Transm (Vienna). 2015;122:187-99 pubmed 出版商
  456. Hayashi A, Suenaga N, Shiomi Y, Nishitani H. PCNA-dependent ubiquitination of Cdt1 and p21 in mammalian cells. Methods Mol Biol. 2014;1170:367-82 pubmed 出版商
  457. Ying Y, Kim J, Westphal S, Long K, Padanilam B. Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol. 2014;25:2707-16 pubmed 出版商
  458. Lu H, Fang E, Sykora P, Kulikowicz T, Zhang Y, Becker K, et al. Senescence induced by RECQL4 dysfunction contributes to Rothmund-Thomson syndrome features in mice. Cell Death Dis. 2014;5:e1226 pubmed 出版商
  459. Leibold T, Hui V, Shia J, Ruby J, Riedel E, Guillem J. p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease. Am J Surg. 2014;208:228-34 pubmed 出版商
  460. Farooqi A, Dagg R, Choi L, Shay J, Reynolds C, Lau L. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. J Neurooncol. 2014;119:17-26 pubmed 出版商
  461. Ram R, Mendiratta S, Bodemann B, Torres M, Eskiocak U, White M. RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression. Mol Cell Biol. 2014;34:2350-8 pubmed 出版商
  462. Machado Neto J, Lazarini M, Favaro P, Franchi G, Nowill A, Saad S, et al. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014;324:137-45 pubmed 出版商
  463. Wojdyla L, Stone A, Sethakorn N, Uppada S, Devito J, Bissonnette M, et al. T-oligo as an anticancer agent in colorectal cancer. Biochem Biophys Res Commun. 2014;446:596-601 pubmed 出版商
  464. Cheng J, Fan Y, Xu X, Dou J, Tang Y, Zhong X, et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014;5:e1079 pubmed 出版商
  465. Okada N, Lin C, Ribeiro M, Biton A, Lai G, He X, et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev. 2014;28:438-50 pubmed 出版商
  466. Berkenkamp B, Susnik N, Baisantry A, Kuznetsova I, Jacobi C, Sörensen Zender I, et al. In vivo and in vitro analysis of age-associated changes and somatic cellular senescence in renal epithelial cells. PLoS ONE. 2014;9:e88071 pubmed 出版商
  467. Shen L, Qu X, Ma Y, Zheng J, Chu D, Liu B, et al. Tumor suppressor NDRG2 tips the balance of oncogenic TGF-? via EMT inhibition in colorectal cancer. Oncogenesis. 2014;3:e86 pubmed 出版商
  468. Fiori M, Barbini C, Haas T, Marroncelli N, Patrizii M, Biffoni M, et al. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 2014;21:774-82 pubmed 出版商
  469. Borkham Kamphorst E, Schaffrath C, Van De Leur E, Haas U, Tihaa L, Meurer S, et al. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-? signaling. Biochim Biophys Acta. 2014;1843:902-14 pubmed 出版商
  470. Aoshiba K, Tsuji T, Itoh M, Semba S, Yamaguchi K, Nakamura H, et al. A murine model of airway fibrosis induced by repeated naphthalene exposure. Exp Toxicol Pathol. 2014;66:169-77 pubmed 出版商
  471. Jackson D, Li H, Mitchell K, Joshi A, Elferink C. Ah receptor-mediated suppression of liver regeneration through NC-XRE-driven p21Cip1 expression. Mol Pharmacol. 2014;85:533-41 pubmed 出版商
  472. Bots M, Verbrugge I, Martin B, Salmon J, Ghisi M, Baker A, et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood. 2014;123:1341-52 pubmed 出版商
  473. Feng Y, Wu H, Xu Y, Zhang Z, Liu T, Lin X, et al. Zinc finger protein 451 is a novel Smad corepressor in transforming growth factor-? signaling. J Biol Chem. 2014;289:2072-83 pubmed 出版商
  474. Tanaka T, Iino M. Knockdown of Sec8 promotes cell-cycle arrest at G1/S phase by inducing p21 via control of FOXO proteins. FEBS J. 2014;281:1068-84 pubmed 出版商
  475. Pospelova T, Bykova T, Zubova S, Katolikova N, Yartzeva N, Pospelov V. Rapamycin induces pluripotent genes associated with avoidance of replicative senescence. Cell Cycle. 2013;12:3841-51 pubmed 出版商
  476. Gastaldello S, Chen X, Callegari S, Masucci M. Caspase-1 promotes Epstein-Barr virus replication by targeting the large tegument protein deneddylase to the nucleus of productively infected cells. PLoS Pathog. 2013;9:e1003664 pubmed 出版商
  477. Sanders Y, Liu H, Zhang X, Hecker L, Bernard K, Desai L, et al. Histone modifications in senescence-associated resistance to apoptosis by oxidative stress. Redox Biol. 2013;1:8-16 pubmed 出版商
  478. Song J, Peng X, Ji M, Ai M, Zhang J, Dong W. Hugl-1 induces apoptosis in esophageal carcinoma cells both in vitro and in vivo. World J Gastroenterol. 2013;19:4127-36 pubmed 出版商
  479. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer M, Minn A, et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol. 2013;15:991-1000 pubmed 出版商
  480. Rajendran P, Kidane A, Yu T, Dashwood W, Bisson W, LOHR C, et al. HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. Epigenetics. 2013;8:612-23 pubmed 出版商
  481. Lauxen I, Oliveira M, Rados P, Lingen M, Nor J, Sant Ana Filho M. Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression. Oral Dis. 2014;20:e76-80 pubmed 出版商
  482. Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser C. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest. 2013;93:768-78 pubmed 出版商
  483. Aoshiba K, Tsuji T, Kameyama S, Itoh M, Semba S, Yamaguchi K, et al. Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. Exp Toxicol Pathol. 2013;65:1053-62 pubmed 出版商
  484. Ma T, Galimberti F, Erkmen C, Memoli V, Chinyengetere F, SEMPERE L, et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther. 2013;12:1545-55 pubmed 出版商
  485. Brochier C, Dennis G, Rivieccio M, McLaughlin K, Coppola G, Ratan R, et al. Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J Neurosci. 2013;33:8621-32 pubmed 出版商
  486. Jelinek M, Balusikova K, Kopperová D, Němcová Fürstová V, Srámek J, Fidlerova J, et al. Caspase-2 is involved in cell death induction by taxanes in breast cancer cells. Cancer Cell Int. 2013;13:42 pubmed 出版商
  487. Parsons M, McCormick L, Janke L, Howard A, Bouchier Hayes L, Green D. Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice. Cell Death Differ. 2013;20:1174-82 pubmed 出版商
  488. Sappino A, Buser R, Seguin Q, Fernet M, Lesne L, Gumy Pause F, et al. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. Oncogenesis. 2012;1:e7 pubmed 出版商
  489. Andrews P, He Z, Tzenov Y, Popadiuk C, Kao K. Evidence of a novel role for Pygopus in rRNA transcription. Biochem J. 2013;453:61-70 pubmed 出版商
  490. Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, et al. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol. 2013;7:484-96 pubmed 出版商
  491. Caldon C, Sergio C, Burgess A, Deans A, Sutherland R, Musgrove E. Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle. 2013;12:606-17 pubmed 出版商
  492. Nakamura K, Aizawa K, Nakabayashi K, Kato N, Yamauchi J, Hata K, et al. DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis. PLoS ONE. 2013;8:e54036 pubmed 出版商
  493. Kuchenreuther M, Weber J. The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation. Oncogene. 2014;33:300-7 pubmed 出版商
  494. Kohn E, Yang Y, Du Z, Nagano Y, Van Schyndle C, Herrmann M, et al. Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. Mol Cancer Res. 2012;10:1389-99 pubmed 出版商
  495. Sundlisaeter E, Edelmann R, Hol J, Sponheim J, Küchler A, WEISS M, et al. The alarmin IL-33 is a notch target in quiescent endothelial cells. Am J Pathol. 2012;181:1099-111 pubmed 出版商
  496. Diril M, Ratnacaram C, Padmakumar V, Du T, Wasser M, Coppola V, et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc Natl Acad Sci U S A. 2012;109:3826-31 pubmed 出版商
  497. Romanov V, Bardin A, Zubova S, Bykova T, Pospelov V, Pospelova T. p21Waf1 is required for complete oncogenic transformation of mouse embryo fibroblasts by E1Aad5 and c-Ha-ras oncogenes. Biochimie. 2011;93:1408-14 pubmed 出版商
  498. Pinho A, Rooman I, Real F. p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle. 2011;10:1312-21 pubmed
  499. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer. 2011;128:1793-803 pubmed 出版商
  500. Yang G, Chang B, Yang F, Guo X, Cai K, Xiao X, et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 2010;16:3171-81 pubmed 出版商
  501. Siatecka M, Lohmann F, Bao S, Bieker J. EKLF directly activates the p21WAF1/CIP1 gene by proximal promoter and novel intronic regulatory regions during erythroid differentiation. Mol Cell Biol. 2010;30:2811-22 pubmed 出版商
  502. Strauss G, Westhoff M, Fischer Posovszky P, Fulda S, Schanbacher M, Eckhoff S, et al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ. 2008;15:332-43 pubmed
  503. Meng L, Kohn K, Pommier Y. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288). Oncogene. 2007;26:4806-16 pubmed
  504. Chen J, Ozanne S. Deep senescent human fibroblasts show diminished DNA damage foci but retain checkpoint capacity to oxidative stress. FEBS Lett. 2006;580:6669-73 pubmed